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CONCOMITANT TARGETING OF THE MTOR/MAPK PATHWAYS: NOVEL
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Advisory Professor: Ignacio I. Wistuba, M.D.

Over the last decade, a paradigm-shift in lung cancer therapy has evolved into
targeted-driven medicinal approaches. However, patients frequently relapse and
develop resistance to available therapies. Herein, we utilized genomic mutation data
from advanced chemorefractory non-small cell lung cancer (NSCLC) patients enrolled
in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer
Elimination (BATTLE-2) clinical trial to characterize novel actionable genomic
alterations potentially of clinical relevance. We identified RICTOR alterations
(mutations, amplifications) in 17% of lung adenocarcinomas and found RICTOR
expression correlates to worse overall survival. There was enrichment of MAPK
pathway genetic aberrations in key oncogenes (e.g. KRAS, BRAF, NF1) associated
with RICTOR altered cases, underscoring that RICTOR could serve as an important
co-oncogenic driver in specific molecular settings. Moreover, we utilized a panel of
RICTOR amplified NSCLC cell lines and found that RICTOR genetic blockade
impaired malignant properties seen by reduced effects on cell survival and
tumorigenicity potential. We uncovered a compensatory activation of the MAPK
signaling pathway following RICTOR knockdown specifically in KRAS co-mutational
settings, exposing a unique therapeutic vulnerability. Our in vitro and in vivo data
vii

testing concomitant pharmacologic inhibition of both pathways (PI3K/AKT/mTOR and
MAPK) via AZD2014 (mTORC1/2 inhibitor) and selumetinib (MEK1/2) resulted in
synergistic responses of antitumor effects. Given the large population of patients
affected by NSCLC, our study provides a treatment rationale for a specific subset of
patients who may benefit from genomic stratification based on RICTOR/KRAS
alterations, further underscoring the need for proper patient selection to gain optimal
therapeutic response.

viii

Table of Contents
Approval signatures ................................................................................................... i
Title page .................................................................................................................... ii
Dedication ................................................................................................................. iii
Acknowledgements .................................................................................................. iv
Abstract .................................................................................................................... vii
Table of contents ...................................................................................................... ix
List of figures ........................................................................................................... xii
List of tables ............................................................................................................. xv
List of abbreviations ............................................................................................... xvi
Chapter 1: Introduction ............................................................................................. 1
1.1 Lung cancer overview ......................................................................................... 1
1.2 Paradigm shift in therapy and molecular characterization of NSCLC ................. 1
1.3 The PI3K/AKT/mTOR signaling pathway ............................................................ 6
1.4 The RAS/RAF/MEK/ERK (MAPK) signaling pathway ....................................... 11
1.5 Cross-talk between PI3K/mTOR and MAPK Pathways .................................... 14
1.6 Therapeutic implications of targeting the PI3K/AKT/mTOR pathway ................ 18
1.7 Therapeutic implications of targeting the RAS/RAF/MEK (MAPK) pathway ..... 21
1.8 RICTOR’s mTORC2-dependent and independent tumorigenic functions ......... 24
1.9 Hypothesis and specific aims ........................................................................... 26
Chapter 2: Materials and Methods.......................................................................... 28
ix

Chapter 3: Results ................................................................................................... 37
3.1 Identification of RICTOR alterations in advanced NSCLC ............................... 37
3.2 RICTOR mRNA expression is higher in RICTOR amplified than non-amplified
NSCLC. .................................................................................................................. 43
3.3 Associating RICTOR mRNA expression to clinical outcome ............................ 44
3.4 Surveying the co-mutational landscape of RICTOR alterations ....................... 44
Chapter 4: Results ................................................................................................... 49
4.1 Selection and mutational background of RICTOR cell line panel ..................... 49
4.2 RICTOR signaling in RICTOR amplified versus non-amplified cell lines .......... 52
4.3 RICTOR knockdown decreases colony formation and anchorage-independent
growth in amplified cells ......................................................................................... 54
4.4 RICTOR knockdown decreases cell proliferation in part through G0/G1 cell cycle
arrest ...................................................................................................................... 54
4.5 RICTOR knockdown reduces the migration and invasion capacity of RICTOR
amplified NSCLC cells ............................................................................................ 58
4.6 RICTOR knockdown results in reduced tumorigenicity in vivo .......................... 62
Chapter 5: Results ................................................................................................... 64
5.1 Compensatory MAPK signaling activation following RICTOR inhibition in KRAS
mutant settings ....................................................................................................... 64
5.2 Compensatory MEK1/2 activation following RICTOR knockdown may be
mediated through de-repression of inhibitory CRAF phosphorylation ..................... 67

x

5.3 Human p-MAPK array reveals RICTOR knockdown affects the activity of several
mediators of cellular stress and survival pathways. ................................................ 71
Chapter 6: Results ................................................................................................... 73
6.1 RICTOR knockdown enhances the pharmacologic efficacy of MAPK pathway
inhibition in RICTOR/KRAS-altered NSCLC cell lines ............................................ 73
6.2 Combined mTORC1/2 and MEK inhibition is an effective therapeutic approach
in RICTOR/KRAS-altered settings and results in synergistic anti-tumor effects
in vitro ..................................................................................................................... 76
6.3 Comparative effects of mTORC1/2 and MEK1/2 pathway inhibition in vivo ...... 82
Chapter 7: Discussion, Conclusions, and Future Directions ............................... 86
Chapter 8: Appendix .............................................................................................. 104
Bibliography ........................................................................................................... 105
Vitae ........................................................................................................................ 138

xi

List of Figures

Figure 1. Non-small cell lung cancer (NSCLC) frequency based on histology .... 2
Figure 2. Frequency of molecular aberrations in various driver oncogenes in
lung adenocarcinomas and current available drugs against these oncogenic
proteins ....................................................................................................................... 4
Figure 3. The mTOR signaling pathway ................................................................... 9
Figure 4. The RAS-RAF-MEK-ERK signaling pathway.......................................... 12
Figure 5. Pathway crosstalk .................................................................................... 17
Figure 6. Identifying novel actionable targets in refractory NSCLC using the
BATTLE-2 clinical trial ............................................................................................. 38
Figure 7. Frequency of potentially actionable genes that carry mutations and/or
amplifications from the NGS FoundationOne targeted panel .............................. 39
Figure 8. RICTOR alterations are present in early and advanced stage lung
adenocarcinoma at similar frequencies ................................................................. 40
Figure 9. Cross-cancer mutational frequency of RICTOR in the TCGA
database ................................................................................................................... 42
Figure 10. Correlation of RICTOR amplification to mRNA gene expression in
lung adenocarcinoma cases ................................................................................... 43
Figure 11. Surveying the co-mutational landscape of RICTOR-altered cases ... 46
Figure 12. Selection of RICTOR cell line panel used for in vitro studies ............ 50
Figure 13. Establishment of inducible shRICTOR cell line models ..................... 50
xii

Figure 14. Comparison of signaling and RICTOR expression in amplified versus
non-amplified cell lines ........................................................................................... 52
Figure 15. RICTOR knockdown decreases colony formation and anchorageindependent growth in amplified cells ................................................................... 55
Figure 16. RICTOR knockdown decreases the cell proliferative capacity .......... 57
Figure 17. RICTOR knockdown reduces migration potential in RICTOR amplified
cell lines .................................................................................................................... 60
Figure 18. RICTOR knockdown reduces invasion potential in RICTOR amplified
cell lines .................................................................................................................... 61
Figure 19. RICTOR knockdown using RICTOR shRNA results in reduced
tumorigenicity in vivo .............................................................................................. 63
Figure 20. Compensatory MAPK signaling activation following RICTOR
knockdown in KRAS mutant settings .................................................................... 66
Figure 21. Compensatory MEK1/2 activation following RICTOR knockdown may
be mediated through de-repression of inhibitory CRAF phosphorylation ......... 70
Figure 22. Human p-MAPK array reveals RICTOR is linked to several mediators
of cellular stress and survival................................................................................. 72
Figure 23. RICTOR knockdown enhances the pharmacologic efficacy of MAPK
pathway inhibition in RICTOR/KRAS-altered NSCLC cell lines ........................... 74

xiii

Figure 24. Combined mTORC1/2 and MEK1/2 inhibition is an effective
therapeutic approach in RICTOR/KRAS-altered in vitro settings ........................ 78
Figure 25. AZD2014 and selumetinib act synergistically to block mTOR and
MAPK pathway signaling in vitro ........................................................................... 80
Figure 26. Selumetinib in combination with shRICTOR or AZD2014 results in the
strongest anti-tumor activity in vivo ...................................................................... 84

xiv

List of Tables

Table 1. Univariate overall survival analysis of RICTOR mRNA expression in
lung adenocarcinoma patients by Cox proportional hazards model .................. 44
Table 2. List of co-mutant genes and their frequency of alterations
(TCGA Lung Adenocarcinoma dataset) ................................................................. 47
Table 3. Mutational profile of RICTOR NSCLC cell line panel .............................. 51

xv

Abbreviations

4EBP1: Eukaryotic Translation Initiation Factor 4E Binding Protein 1
AKT: V-Akt Murine Thymoma Viral Oncogene Homolog 1
ALK: Anaplastic Lymphoma Receptor Tyrosine Kinase
AMPK: AMP-activated protein kinase
ARAF/BRAF/CRAF: A/B/C-Raf Proto-Oncogene, Serine/Threonine Kinase
ARFRP1: ADP Ribosylation Factor Related Protein 1
ATCC: American Type Culture Collection
ATM: Ataxia Telangiectasia Mutated
ATR: Ataxia Telangiectasia And Rad3-Related Protein
AZD2014: Vistusertib
AZD6244: Selumetinib
BATTLE-2: The Biomarker-integrated Approaches of Targeted Therapy for Lung
Cancer Elimination trial
BCL2L2: BCL2 Like 2
BCL6: B-Cell CLL/Lymphoma 6
CAV1: Caveolin 1
CCLC: Characterized Cell Line Core
CCLE: Cancer cell line encyclopedia
xvi

CCND1: Cyclin D1
CCNE1: Cyclin E1
CDC42: Cell Division Cycle 42
CDK4: Cyclin Dependent Kinase 4
CEBPA: CCAAT/Enhancer Binding Protein Alpha
CI: Confidence interval
CNV: Copy number variation
CREB: CAMP Responsive Element Binding Protein 1
CRISPR/Cas9: Clustered regularly interspaced short palindromic repeats/CRISPR
associated protein-9
CRKL: CRK Like Proto-Oncogene, Adaptor Protein
CUL1: Cullin-1
CUL3: Cullin-3
DEPTOR: DEP Domain Containing MTOR-Interacting Protein
DMSO: Dimethyl sulfoxide
DNA-PK: Protein Kinase, DNA-Activated, Catalytic Polypeptide
Doxy: Doxycycline
EGFR: Epidermal Growth Factor Receptor
eIF: Eukaryotic translation initiation factors
xvii

EMT: Epithelial-to-mesenchymal transition
ER positive: Estrogen receptor positive
ERBB2: Erb-B2 Receptor Tyrosine Kinase 2
ERK1/2: Mitogen-Activated Protein Kinase 1/3
EZH2: Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit
FGF-19, 3, 10, 4, 12: Fibroblast Growth Factor 19, 3, 10, 4, or 12
FGFR1: Fibroblast Growth Factor Receptor 1
FKBP12: FK506 binding protein 12
FOXO: Forkhead box O family of proteins
GAPs: GTPase-activating protein
GEFs: Guanine nucleotide exchange factors
GPR124: G-Protein Coupled Receptor 124
GRB2: Growth Factor Receptor Bound Protein 2
GSK3: Glycogen Synthase Kinase 3 Beta
GSK3a/b: Glycogen Synthase Kinase 3 Alpha/Beta
HBEC: Immortalized human bronchial epithelial cells
HGF: Hepatocyte Growth Factor
HR: Hazard ratio
HRAS: Harvey Rat Sarcoma Viral Oncogene Homolog
xviii

HSP27: Heat Shock 27kDa Protein 1
IKZF1: IKAROS Family Zinc Finger 1
IL7R: Interleukin 7 Receptor
ILK: Integrin linked kinase
IRS: Insulin receptor substrate
JNK: c-Jun N-terminal kinases
KDR: Kinase Insert Domain Receptor
KEAP1: Kelch Like ECH Associated Protein 1
KIT: KIT Proto-Oncogene Receptor Tyrosine Kinase
KLHL6: Kelch Like Family Member 6
KRAS: Kirsten Rat Sarcoma Viral Oncogene Homolog
MAP3K13: Mitogen-Activated Protein Kinase Kinase Kinase 13
MAPK: Mitogen-Activated Protein Kinase
MBN: Proteinase 3
MDM2: MDM2 Proto-Oncogene, E3 Ubiquitin Protein Ligase
MEK1/2: Mitogen-Activated Protein Kinase Kinase 1/2
MET: MET Proto-Oncogene, Receptor Tyrosine Kinase
mLST8: MTOR Associated Protein, LST8 Homolog
MMP9: Matrix Metalloproteinase 9
xix

mSIN1: Mitogen-Activated Protein Kinase Associated Protein 1
mTOR: Mechanistic Target Of Rapamycin
mTORC1/2: Mechanistic Target Of Rapamycin Complex 1/2
MTS: (3-4, 5-dimethyl-thiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-solfophenyl)-2Htetrazolium)
MTT: Methylthiazolyldiphenyl-tetrazolium bromide
MYC: V-Myc Avian Myelocytomatosis Viral Oncogene Homolog
NDRG1: N-Myc Downstream Regulated 1
NF1: Neurofibromin 1
NFE2L2: Nuclear Factor, Erythroid 2 Like 2
NFkB1A: Nuclear Factor Kappa B Subunit 1
NGS: Next-generation sequencing
NKX2-1: NK2 Homeobox 1
NRAS: Neuroblastoma RAS Viral Oncogene Homolog
NSCLC: Non-small cell lung cancer
NTC: Non-targeting control (shRNA or siRNA)
OS: Overall survival
P38: Mitogen-Activated Protein Kinase 14
P53: Tumor Protein P53
xx

P70S6K: Ribosomal Protein S6 Kinase B1
PDK1: Pyruvate Dehydrogenase Kinase 1
PET: Polyethylene terephthalate filters
PH domain: Pleckstrin homology domain
PI3K: Phosphoinositide 3-kinase
PIK3CA: Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
PIK3R1: Phosphoinositide-3-Kinase Regulatory Subunit 1
PIKK family: Phosphatidylinositol 3-kinase-related kinases
PIP2: Phosphatidylinositol-4,5-bisphosphate
PIP3: Phosphatidylinositol-3,4,5-trisphosphate
PKB: Protein kinase B
PKC: Protein kinase C
PMS2: PMS1 Homolog 2, Mismatch Repair System Component
PRAS40: Proline-rich AKT1 substrate 1
PROSPECT: Profiling of Resistance Patterns and Oncogenic Signaling Pathways in
Evaluation of the Thorax dataset
PROTOR-1: Protein observed with Rictor-1
PTB domains: Phosphotyrosine-binding domains
PTEN: Phosphatase And Tensin Homolog
xxi

RAC1: Ras-Related C3 Botulinum Toxin Substrate 1 (Rho Family, Small GTP Binding
Protein Rac1
RalA: RAS Like Proto-Oncogene A
RAPTOR: Regulatory Associated Protein Of MTOR Complex 1
RBX1: Ring-Box 1
RET: RET proto-oncogene
RHEB: Ras Homolog Enriched In Brain
RhoA: Ras Homolog Family Member A
RhoGAP5: Rho GTPase Activating Protein 5
RhoGDI: Rho GDP-dissociation inhibitor
RICTOR: RPTOR Independent Companion Of MTOR Complex 2
RIT1: Ras-Like Without CAAX 1
ROS1: ROS Proto-Oncogene 1, Receptor Tyrosine Kinase
RSK: Ribosomal S6 kinase
RTKs: Receptor tyrosine kinases
RUNX1T1: RUNX1 Translocation Partner 1
S6RP: S6 ribosomal protein
SCLC: Small cell lung cancer
SGK: Serum/Glucocorticoid Regulated Kinase
xxii

SH2 domains: Src Homology 2 domain
SNP array: Single nucleotide polymorphism array
SOS: Son of sevenless
SOX2: SRY-Box 2
STK11: Serine/Threonine Kinase 11; LKB1
TCGA: The Cancer Genome Atlas
TGFβ: Transforming Growth Factor Beta 1
TIPARP: TCDD Inducible Poly(ADP-Ribose) Polymerase
TKIs: Tyrosine kinase inhibitors
TSC1/2: Tuberous Sclerosis 1/2
VEGFR: Vascular Endothelial Growth Factor Receptor 1
WD40 domain: WD or beta-transducin repeats
ZNF703: Zinc Finger Protein 703

xxiii

Chapter 1
Introduction
1.1 Lung Cancer Overview
Lung cancer continues to affect the lives of more than 1.6 million new patients
annually and remains a major global health problem. It is estimated to affect more
than 224,000 people and lead to over 159,000 new deaths in the US each year (1).
Despite advancements in detection methods and standard of care, over a third of
patients that are diagnosed with lung cancer present at late stage with metastatic
disease, resulting in a dismal 5-year survival rate of less than 5% which has remained
stagnant over the past few decades (2). What was once considered a single disease
entity, lung tumors exist as diverse subtypes with unique pathologies. The two major
forms of lung cancer are non-small cell lung cancer (NSCLC) (accounts for
approximately 85% of all lung tumors) and small-cell lung cancer (SCLC) (about
15%). Specifically, NSCLC can be further subdivided into three major histotypes: lung
adenocarcinoma (50%), squamous-cell carcinoma (30%), and large-cell lung cancer
(15%) (Figure 1) (3).
1.2 Paradigm Shift in Therapy and Molecular Characterization of NSCLC
It is well recognized that heterogeneity amongst the molecular architecture of
tumors is responsible for diverse clinical outcomes and responses even in patients
with similar clinical staging and histologic characteristics. This is due to our increased
understanding that NSCLC is a disease comprised of diverse clinical, histological, and
genetically distinct subtypes.
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NSCLC by histology
Large
Cell
15%
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5%
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30%

Adenocarcinoma
50%

Figure 1. Non-small cell lung cancer (NSCLC) frequency based on histology.

With significant advancements in genomic sequencing technologies, treatment
strategies and management of NSCLC, particularly in lung adenocarcinomas, are
heavily based on screening tumors for an array of biomarkers that are of predicative
and/or prognostic value to help oncologists assign patients that would be most
sensitive to specific targeted therapies (4). A multitude of oncogenic driver mutations
that feed into key signaling pathways have now been elucidated that lead to
tumorigenesis and tumor progression (Figure 2) (5). Specifically, significant effort in
the last decade had centered upon developing targeted agents against mutations of
the epidermal growth factor receptor (EGFR, ~17% mutations) and in anaplastic
lymphoma kinase (ALK) fusions/rearrangements (~7%), with much success attributed
to examples such as EGFR tyrosine kinase inhibitors (TKIs) and crizotinib,
respectively. In both subgroups, the response rates in patients properly stratified to
2

these targeting agents were as high as 70% in crucial phase 3 clinical trials (6, 7).
Identification of such driver mutations and the responses seen in patients
appropriately stratified serve as classic examples for the impetus of rational design of
new and improved targeted agents that hit other key oncogenes in NSCLC. Such
alterations are often found in receptors or protein kinases and can activate a complex
cascade of oncogenic signaling paths such as the mitogen-activated protein kinase
(MAPK) cascade and the phosphoinositide 3-kinase (PI3K)-PKB (AKT) pathway. The
frequency of other genomic alterations that occur in lung adenocarcinomas include
KRAS (25%), NF1 (8.3%), MET (3%), ROS1 (2%), BRAF (2%), RET (2%), and others
(Figure 2) (5, 8). Ultimately, these mutant onco-drivers stimulate such pathways that
lead to uncontrolled cancer cell growth, proliferation and pro-survival transcriptional
reprogramming (9-12). However, approximately 25-30% of lung adenocarcinomas do
not have known, targetable mutations, and therefore these patients are treated with
standard cytotoxic chemotherapies with limited success. Moreover, although targeted
therapies against discovered alterations lead to remarkable initial responses, the
inevitable emergence of drug resistance still occurs and patients ultimately relapse.
Mechanisms of resistance can occur either through the acquisition of secondary
mutations in the targeted kinase that can potentially negate the drug binding affinity,
or by compensating via alternate bypass signaling mechanisms, though other
resistance mechanisms are possible (13, 14). Therefore, it is imperative to take into
account the molecular underpinnings of each patient’s tumor and utilize a
personalized medicine approach to identify novel actionable targets and therapeutic
strategies tailored to that individual.

3

Figure 2. Frequency of molecular aberrations in various driver oncogenes in
lung adenocarcinomas and current available drugs against these oncogenic
proteins. These frequencies are a combination of data from the Lung Cancer
Mutation Consortium and frequencies listed in Shea et al. (15). Shown in the boxes
are the available drugs in addition to their developmental phase. EGFR, epidermal
growth factor receptor; ALK, anaplastic lymphoma receptor tyrosine kinase; MET,
mesenchymal-to-epithelial transition factor; HER2, erb-b2 receptor tyrosine kinase 2;
ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; BRAF, B-Raf protooncogene, serine/threonine kinase; RET, ret proto-oncogene; NTRK1, neurotrophic
4

tyrosine kinase receptor type 1; PIK3A, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha; MEK1, mitogen-activate protein kinase kinase 1;
KRAS, Kirsten rat sarcoma viral oncogene homolog.
Reprinted with permission from: Tsao AS et al. Scientific Advances in Lung Cancer
2015. J Thorac Oncol. 2016;11(5):613-38. (5) License # 3957960028670
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1.3 The PI3K/AKT/mTOR signaling pathway
The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB/AKT)mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway is one of the
most frequently deregulated signaling pathways in cancer and heavily enhances
tumorigenic potential with its regulatory processes involving cellular growth,
proliferation, survival, migration/invasion, and angiogenesis (16-18) (Figure 3). Under
physiological condition, this intricate pathway is stimulated via ligand activation of
receptor tyrosine kinases (RTKs) such as EGFR, ErbB3 IGF1-R, resulting in
phosphorylation of tyrosine residues on the intracellular portion of the receptors (16,
19). This results in the direct recruitment of PI3K to the membrane of the cell where
conversion of the second messenger phosphatidylinositol-4,5-bisphosphate (PIP2) to
phosphatidylinositol-3,4,5-trisphosphate (PIP3) can occur (20). PIP3 is then able to
recruit 3-phosphoinositide dependent protein kinase-1 (PDK1) and the
serine/threonine kinase AKT, via their pleckstrin homology (PH) domains, to the
plasma membrane. PDK1 then phosphorylates AKT on Thr308 in the catalytic domain
and the mammalian target of rapamycin complex 2 (mTORC2) serves to fully activate
AKT on Ser473 in the hydrophobic motif (21). Active AKT mediates numerous cellular
processes including survival, proliferation, apoptosis, migration and invasion via
regulation of downstream effectors spanning multiple pathways (22-27). Typically,
AKT can then lead to phosphorylation and inactivation of the GTPase-activating
proteins (GAPs) tuberous sclerosis 1 and 2 (TSC1/TSC2), resulting in the
accumulation of GTP-bound Ras homologue enriched in brain (RHEB) ultimately
leading to activation of mammalian target of rapamycin complex 1 (mTORC1). Once
activated, mTORC1 can directly regulate cellular processes involved in metabolism
6

and biosynthesis. Specifically, mTORC1 phosphorylates p70 S6 kinase and the
translation repressor 4E-binding protein 1 (4EBP1). Phosphorylation of 4EBP1 inhibits
the binding ability to eIF4E and initiates cap-dependent translation (28, 29). Similarly,
S6K activation aids in the cap-dependent translation mechanism and also promotes
S6 ribosomal protein (S6RP) phosphorylation. Collectively, this pathway converges on
important cellular mechanisms resulting in increased protein translation, ribosome
biogenesis and inhibition of autophagy (30-32).
Moreover, key components of the mTOR pathway are the two structurally and
functionally distinct mTOR complexes. The essential mTORC1 subunits are the
Ser/Thr kinase mTOR, the regulatory-associated protein of mTOR (RAPTOR) which
serves as a scaffolding unit, mammalian lethal with Sec13 protein 8 (mLST8), prolinerich AKT substrate 40 kDa (PRAS40), and DEP-domain-containing mTOR-interacting
protein (DEPTOR) (33, 34). The functional and regulatory mechanisms of mTORC1
have been characterized extensively since the discovery of rapamycin, an antifungal
metabolite produced from the bacterium Streptomyces hygroscopicus, which inhibits
mTOR and was later discovered to exhibit anti-proliferative and immunosuppressive
effects (35). mTORC1 activity can be modulated by amino acid availability, nutrient
levels, cellular energy status, and growth factors and ultimately coordinates regulatory
signaling for translation and ribosome biogenesis (as described above). Moreover,
mTORC1 is directly linked to the regulation of autophagy, and this link has been
extensively studied due to important implications to cancer biology and treatment (36,
37). The process of autophagy can be either pro-oncogenic, acting as a survival
mechanism to aid in growth advantage during stressful cellular conditions, or tumor
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suppressive in function by preventing the buildup of damaged molecules such as
organelles and proteins (37-40).
mTOR can function as part of a second complex, mTORC2, which contains
some overlapping and distinct protein subunits, namely rapamycin-insensitive
companion of mTOR (RICTOR), mammalian stress-activated protein kinase
interacting protein (mSIN1), protein observed with Rictor-1 (PROTOR-1), DEPTOR,
and mLST8 (36). Relative to mTORC1, the biology of regulation and functionality of
mTORC2 is still in its infancy, although there is increased appreciation of the
importance of this complex. Further, although it is established that activation of
mTORC2 can be mediated by growth factors and PI3K signaling, the precise
mechanism is poorly understood. One of the major roles elucidated for mTORC2 is
the phosphorylation and full activation of AKT on Ser473 (21, 41). It can also
phosphorylate and activate several other protein A/G/C (AGC) kinase family members
such as serum glucocorticoid-induced kinase (SGK) and protein kinase C (PKC)
isoforms, regulating cytoskeletal reorganization, cell survival, and lipid metabolism
(41-43).
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Figure 3. The mTOR signaling pathway. Red lines indicate the different
mechanisms of mTOR activation. Abbreviations: AMPK, AMP-activated kinase;
deptor, DEP-domain-containing mTOR interacting protein; 4E-BP1, eIF4E-binding
protein 1; eIF, eukaryotic initiation factors; ERK1/2, extra-cellular regulated kinase 1/2;
FKBP12, FK506 binding protein 12; IRS, Insulin receptor substrates; mLST8,
mammalian lethal with Sec13 protein 8; mTORC, mammalian target of rapamycin
complex; NDRG1, N-Myc downstream regulated gene-1; PDK1, phosphoinositidedependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol
bisphosphate; PIP3, phosphatidylinositol triphosphate; PRAS40, proline-rich Akt1
substrate 1; protor, protein observed with Rictor-1/Proline rich Akt substrate of 40kDa;
P70S6K1, p70 S6 kinase 1; Rheb, Ras homolog enriched in brain; mSin1, stress
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activated protein kinase interaction protein 1; SGK, serum and glucocorticoid protein
kinase; TSC, tuberous sclerosis complex; TKR, tyrosine kinase receptor.
Reprinted with permission from: Chapuis N. et al. Perspectives on inhibiting mTOR as
a future treatment strategy for hematological malignancies. Leukemia. 2010;24
(10):1686-99 (44). License # 3960460046414
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1.4 The RAS/RAF/MEK/ERK (MAPK) signaling pathway
The mitogen-activated protein kinase (MAPK) signaling pathway is a highly
conserved family of kinases and is deregulated in about one-third of all human
cancers (45). An overview of this signaling pathway is illustrated in Figure 4 (46). This
pathway is primarily induced by cell surface receptors such as RTKs. Dimerization of
these receptors following ligand binding activates the receptors and
autophosphorylation of tyrosine residues occurs in the intracellular domain.
Phosphorylation of these residues acts as docking sites for various proteins
containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains (e.g.
Grb2, growth factor receptor-bound protein 2). Grb2, serving as an adaptor molecule,
can then recruit son of sevenless (SOS), a GTPase exchange factor (RasGEF), to
localize to the cell membrane. Inactive Ras-GDP is largely associated with the plasma
membrane, but following activation and catalytic transformation to Ras-GTP by SOS,
RAS is able to recruit the RAF family of kinases (A-RAF, B-RAF, C-RAF) to the
membrane and activate them. Subsequent activation loop phosphorylations occur in
which RAF activates downstream MEK1/2, and MEK1/2 ultimately activates ERK1/2
at threonine and tyrosine residues, leading to a cascade of reactions regulating cell
survival, proliferation, and motility. The main downstream targets elucidated of
MEK1/2 are ERK1/2, while ERK1/2 has numerous downstream effectors (47).
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Figure 4. The RAS-RAF-MEK-ERK signaling pathway. The classical MAPK
pathway is activated in human tumors by several mechanisms including the binding of
ligand to receptor tyrosine kinases (RTK), mutational activation of an RTK, by loss of
the tumor suppressor NF1, or by mutations in RAS, BRAF, and MEK1.
Phosphorylation and thus activation of ERK regulates transcription of target genes
that promote cell cycle progression and tumor survival. The ERK pathway contains a
classical feedback loop in which the expression of feedback elements such as SPRY
and DUSP family proteins are regulated by the level of ERK activity. Loss of
expression of SPRY and DUSP family members due to promoter methylation or
12

deletion is thus permissive for persistently elevated pathway output. In the case of
tumors with V600EBRAF expression, pathway output is enhanced by impaired
upstream feedback regulation.
Reprinted with permission from: Pratilas CA, Solit DB. Targeting the mitogenactivated protein kinase pathway: physiological feedback and drug response. Clinical
cancer research: an official journal of the American Association for Cancer Research.
2010;16(13):3329-34. (46) License # 3960600731382
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1.5 Cross-talk between PI3K/mTOR and MAPK Pathways
Traditional views of major signaling networks such as the PI3K/AKT/mTOR and
RAS/RAF/MEK/ERK (MAPK) pathways arrange these mechanisms as linear and
independent pathways that determine cellular fate. However, numerous reports to
date have described that these parallel pathways are very intricate and in fact there
are multiple nodes of cross-talk, resulting in cross-activation, inhibition, and
convergence of pathways on effector targets (48, 49). This is evidenced by reports
suggesting that approximately 802 active proteins exist that are involved in PI3Kmediated signaling and over 2,000 connections exist that relate to the MAPK pathway
family kinases (50, 51). Thus, the opportunity for cross-regulatory mechanisms
amongst these interactomes to occur is not surprising and both of these major
oncogenic pathways affect each other at various phases of signal transduction,
depending on the cellular context and need. A summary of major cross-talk
mechanisms that have been reported are highlighted in Figure 5 (49).
In both pathways, there are various kinases that have limited specificity of
known substrates (e.g. mTORC1, RAF, MEK) and others that activate various
members of their respective pathways on top of a multitude of other effector targets
(e.g. S6K, ERK, AKT, RSK) (49). The integration of the PI3K/mTOR and MAPK
pathways therefore mostly occurs through the latter kinases noted. Cross-inhibition of
these pathways has been elucidated following studies utilizing chemical methods of
blockade, wherein one pathway is blocked inducing a release mechanism of the basal
cross-inhibitory effects leading to activation of the alternate pathway. For instance,
inhibitors of MEK have been shown to increase epidermal growth factor (EGF)-
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mediated activation of AKT through the recruitment of PI3K to the EGFR receptor (52,
53).
Moreover, a cross-inhibitory mechanism between RAF and AKT has been
proposed that is induced by levels of IGF1 stimulation (54). Studies reported that the
negative regulations of downstream ERK signaling by AKT occur through AKT’s
inhibition on phosphorylation sites in the upstream RAF N-terminus domain,
specifically on the Ser364/259 residues (55-57). These conserved sites are
recognized by 14-3-3 dimers which can immobilize the auto-inhibited RAF in the
cytosolic region away from its upstream and downstream effectors RAS and MEK,
respectively (58).
Cross-activation can also occur between both pathways. The MAPK pathway
can activate the PI3K/mTOR pathway through direct regulation of PI3K, mTORC1,
and TSC2. Activated RAS, when bound to GTP, can allosterically activate PI3K
through direct binding (59-61). Moreover, constitutive activation from a mutant RAS,
EGF stimulation, or phorbol esters can lead to hyperactive MAPK signaling, resulting
in ERK and its effector ribosomal s6 kinase (RSK) to stimulate mTORC1 activity by
inhibiting the GTPase-activating protein (GAP) function of the TSC1/2 complex (62).
Additionally, pathway convergence can occur via multiple mechanisms signaled by
S6K, AKT, ERK, and RSK since these key proteins share similar substrates and
sometimes activate the same target simultaneously to fulfill specific processes such
as cell survival, proliferation, motility and metabolism. Prime examples include the
regulation of the forkhead box O (FOXO) and glycogen synthase kinase 3 (GSK3)
(49). The FOXO family of proteins control expression of molecules involved in the
apoptotic cascade and key cell cycle regulators, with the primary role of inhibiting cell
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survival and proliferation. ERK, AKT, and SGK can all phosphorylate various
members of the FOXO proteins on specific residues that lead to their ultimate
degradation and sequestration, therefore restricting their nuclear translocation and
preventing apoptotic transcriptional machinery (63-66). Moreover, GSK3 can be
directly regulated by ERK, AKT, PKC, and S6K. GSK3 functions to inhibit survival,
proliferation, and motility targets including beta-catenin and various adhesion proteins.
It can also phosphorylate and activate TSC2 and lead to inactivation of mTORC1
signaling (67).
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Figure 5. Pathway Crosstalk. The Ras-MAPK and PI3K-mTORC1 pathways
regulate each other via cross-inhibition (red) and cross-activation (green). Each
pathway has a mechanism to negatively feed onto the other: ERK phosphorylation of
GAB and AKT phosphorylation of Raf. Components of the Ras-ERK pathway (Ras,
Raf, ERK, and RSK) also positively regulate the PI3K-mTORC1 pathway. TSC2 and
mTORC1 are key integration points that receive many inputs from both the Ras-ERK
and PI3K signaling. Positive regulation of the substrate protein is shown as an arrow.
Negative regulation of the substrate protein is depicted as a blunt-ended line.
Reprinted with permission from: Mendoza MC, Er EE, Blenis J. The Ras-ERK and
PI3K-mTOR pathways: cross-talk and compensation. Trends in biochemical sciences.
2011;36(6):320-8. doi: 10.1016/j.tibs.2011.03.006. (49) License # 3961020803450
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1.6 Therapeutic implications of targeting the PI3K/AKT/mTOR pathway
NSCLC harbors molecular alterations involving the PI3K/AKT/mTOR and
MAPK pathways, and thus, pharmacologic inhibitors of both pathways are given
extensive priority for development to further test in the clinic. Deregulations of the
PI3K/AKT/mTOR pathway occur at variable frequencies in lung tumorigenesis and
have been correlated with more advanced stage disease as well as tumor grade (68).
Aberrant mechanisms of activation can occur through a variety of ways, including
upregulation of RTK activity upstream of PI3K, amplification and/or mutations in
PIK3CA, KRAS, STK11, AKT, or inactivating mutations in the negative regulator
phosphatase and tensin homolog (PTEN) (69). Collectively, targeting these pathways
remains both an opportunity and a challenge for cancer treatment.
The earliest mTOR inhibitor discovered was rapamycin and was initially
developed for use as an active anti-fungal and immunosuppressive agent. The antiproliferative effects first seen in studies involving cancer cell lines led to the active
interest in the mTOR pathway as a potential anti-cancer target of interest. The
mechanism by which rapamycin exerts its effects is by allosteric inhibition of the
mTORC1 complex with high affinity to the FKBP-12/rapamycin binding (FRB) domain
of mTOR (70). Additionally, rapamycin has been shown to selectively inhibit mTORC1
activity and have minimal effects against mTORC2; although extended treatments
have shown to increase sensitivity of this complex to the drug in some cellular
contexts (71). The general effects seen in the clinic with rapamycin have been modest
and mainly result in stability of disease. Analogs of rapamycin have since been
developed, which have similar molecular structures but differing physiochemical
properties. Examples of these rapalogs include everolimus, temsirolimus, and
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deforolimus, and have undergone numerous clinical trials in a wide range of cancers.
Thus far, everolimus and temsirolimus have been approved for advanced renal cell
carcinoma (72, 73). To increase the anti-tumor response, numerous strategies have
been proposed including the combinations of rapalogs with chemotherapeutic drugs
to induce cell death or combining targeted therapies specific for the PI3K/AKT/mTOR
pathway or parallel pathways.
Moreover, one of the major limitations in the effectiveness of rapalogs has
been the discovery of de-repression of negative feedback loops mediated by
mTORC1. Studies have elucidated that mTORC1 inhibition releases a negative
feedback loop on the insulin receptor substrate (IRS-1) and growth-factor-receptorbound protein 10 (GRB10), resulting in increased RTK signaling to PI3K, AKT, and/or
to other pathways through ERK1/2. Also, rapalogs have been shown to shut down
downstream S6K signaling completely, but only inhibit the translational repressor
4EBP1 transiently, therefore protein synthesis, cell proliferation and survival
mechanisms can still continue to occur (69, 74, 75). The increased understanding of
the drawbacks of first generation mTOR inhibitors resulted in the advent of new
catalytic ATP-competitive inhibitors being developed targeting the mTOR kinase
domain, with the expectation to inhibit both of the critical mTORC1 and mTORC2
complexes and prevent feedback activation of AKT (76, 77). Early clinical trials
identified mTORC1/2 inhibitors having superior single agent activity compared with
previous rapalogs. Partial responses have been reported in NSCLC, estrogen
receptor (ER) positive breast cancer, and hepatocellular carcinoma using either of two
mTORC1/2 inhibitors (AZD2014 and CC-223); however, optimized patient selection is
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still further warranted and these drugs have not yet reached the initial expectations as
single agents (78, 79).
The critical role of PI3K in cancer led to significant efforts in developing drugs
targeting it, many of which are still undergoing clinical evaluation in various phases of
trials. There are three distinct PI3K classes which are further subdivided into varying
isoforms. Class IA PI3Ks are the most studied and are made up of a p110 catalytic
subunit (encoded by three homologous isoforms: p110α, p110β and p110δ) and a
p85 regulatory subunit (16). Compared to other targeted drugs aimed at oncogenic
kinases (e.g. EGFR, RAF, ALK), inhibitors against PI3K have had limited efficacy as
single arm treatments in early phase clinical trials in tumors that harbored PI3K
pathway hyperactivation (18). First generation pan-PI3K inhibitors were initially
developed, such as wortmannin and LY294002, but were hindered in early phases of
human trials due to their toxicities and lack of specificity. Most of these inhibitors in
early clinical trials are catalytic ATP-competitive inhibitors and target all class I PI3K
isoforms with similar effectiveness. This could be problematic in that these drugs
target all the class I PI3K isoforms regardless of their actual oncogenic role, and
moreover, have been shown to display off-target effects on other effectors of the
phosphatidylinositol 3-kinase-related kinases (PIKK) family, including ATM
Serine/Threonine Kinase (ATM), Ataxia Telangiectasia And Rad3-Related Protein
(ATR), and DNA-dependent Protein Kinase (DNA-PK) (80, 81). Therefore, isoformspecific inhibitors are now being developed for clinical testing with the expectation for
achieving better safety and efficacy profiles and reduce toxicity. Determining the
specific disease settings by which the different PI3K isoforms contribute to the
tumorigenic phenotype will be crucial to increase the effectiveness of these inhibitors.
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Furthermore, AKT inhibitors have also been developed, particularly since this
master regulator integrates the central node of the PI3K/mTOR pathway. Several ATP
mimetics and inhibitors of non-catalytic sites of AKT have been pushed into the clinic
for evaluation. Although AKT1 activating mutations occur infrequently in NSCLC,
overexpression of AKT1 and AKT2 occurs at higher rates, exposing possible
therapeutic vulnerability to these AKT inhibitory agents (69, 82). However, early phase
trials have shown, at best, stability in disease as the most encouraging overall
response with anti-proliferative, rather than anti-tumorigenic, effects mediated by
single agent therapy (83, 84). Furthermore, experimental models and early clinical
trials have suggested that AKT-specific inhibitors may be most efficacious in specific
molecular settings, particularly in tumors harboring PTEN loss or PIK3CA mutations,
leading to the hyperactivity of the AKT mediated pathway. Importantly, resistance
mechanisms such as the relief of mTORC1 feedback inhibition on IRS-1 signaling
(mentioned above), and de-repression of FOXO leading to increased activation of
RTKs, PI3K, PDK1, and other targets downstream of AKT, have been also elucidated
(85). In all, AKT inhibitors are being approached with caution as their disturbance to
the AKT pathway can lead to metabolic dysregulations and hyperglycemia (86).
1.7 Therapeutic implications of targeting the RAS/RAF/MEK (MAPK) pathway
Three RAS genes (HRAS, NRAS, KRAS) have been identified and aberrant
mutations in these isoforms have been discovered to have major oncogenic
implications. Specifically, KRAS mutations are the most prevalent and have been
found in 1/3 of all cancers, including colon, pancreatic, and lung. The most frequent
codons of KRAS that are mutated in lung cancers occur at codons 12, 13 and 61 (87).
Mutations in this oncogene result in a constitutively active KRAS leading to
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hyperactivity of the MAPK and mTOR pathways. For over two decades, numerous
strategies were attempted to target oncogenic KRAS signaling, including direct
inhibitors of the protein, RNA interference, inhibitors that prevent localization of RAS
to the membrane, and targeting drugs of downstream effectors (88). One of the
earliest efforts to block RAS was through abrogation of its localization via
farnesylation to the plasma membrane via farnesyl transferase inhibitors. However,
this drug class failed when pursued for evaluation in pre-defined mutant KRAS
cancers, since eventual recognition that KRAS could be alternatively modified via
other mechanisms to relieve the translocation repression, ultimately allowed KRAS
back to the plasma membrane even in the absence of farnesylation (89).
Refocused therapeutic strategies have gained momentum over the years by
developing targeted therapies against effectors downstream of KRAS. Notably, the
identification of BRAF mutations in melanomas have sparked clinical testing of
multiple RAF kinase inhibitors. BRAF mutations have been reported in about 2-3% of
lung adenocarcinomas. Based on previous marked anti-tumor activity in BRAFV600E
mutant melanoma, mutant BRAF inhibitors (e.g. dabrafenib, vemurafenib) have made
it into clinical evaluation for advanced stage BRAF positive NSCLC (90). However, the
efficacy of these inhibitors in the KRAS mutant setting still remains to be resolved as
responses with single agent RAF inhibitors have been poor, specifically in KRAS
mutant settings. Studies have elucidated paradoxical reactivation of downstream
ERK1/2 following BRAF inhibition. Specifically, BRAF inhibitors resulted in either relief
of RAF-inhibitory autophosphorylation mechanisms or RAF inhibitor-induced
transactivation of RAF dimerization, leading to increased ERK signaling (91-94).
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Thus, combination regimens to combat such bypass mechanisms of resistance are
still being established and evaluated in the clinical setting.
Resistance mechanisms of RAF inhibition prompted avid development of
downstream MEK targeted therapies with the hopes of more durable pathway
inhibition. Selumetinib and trametinib are two allosteric MEK1/2 inhibitors that have
been evaluated as either single agents or in combination with cytotoxic agents to
target mutant KRAS NSCLC. Early stage clinical trials showed that selumetinib as a
single agent led to tumor responses in advanced cancer patients; however, phase II
trials in selected patient populations with previously treated NSCLC (including some
patients with KRAS mutations) showed little clinical activity (95, 96). Further, based on
pre-clinical in vivo evidence, studies showed that cytotoxic agents such as docetaxel
in combination with selumetinib resulted in synergistic anti-tumor effects, and thus
sparked clinical trials of this dual combination. Results from a phase II trial evaluating
this combination in advanced stage (III-IV) chemo-refractory KRAS mutant NSCLC
patients found a trend in better overall survival (OS), but the study failed to meet the
primary endpoint, and only a fraction of the patients were partial responders (97). In
addition, trametinib has also been examined in the clinic. A phase II trial evaluating
trametinib as monotherapy versus docetaxel in KRAS mutant NSCLC resulted in no
statistically significant or clinically meaningful endpoints (98). Current studies are
evaluating the combination of trametinib with chemotherapy drugs such as docetaxel
or pemetrexed. Collectively, it can be concluded that although MEK inhibitors can
have the potential for significant anti-tumor effects, better patient selection,
optimization of dosing regimens, and rational combinatorial therapeutic strategies are
necessary to find significant clinical utility of these agents.
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1.8 RICTOR’s mTORC2-dependent and independent tumorigenic functions
The mTORC2 complex is comprised of mTOR and the essential components
RICTOR, mSIN1, and mLST8. This complex regulates a variety of important cellular
functions including proliferation, survival, and metabolism through phosphorylation of
various AGC kinase family members such as AKT, PKCα, and SGK (99). RICTOR
and mSIN1 function as adaptor molecules serving as critical regulators of mTORC2
substrate specificity and binding. Specifically, RICTOR’s Gly-934 residue is critical in
the formation of the RICTOR/mSIN1 heterodimer interaction required for the structural
integrity, stability, and functionality of the complex (100).
Increasing reports have elucidated the contribution of RICTOR toward
tumorigenic phenotypes functioning through mTORC2-dependent and independent
manners. Initially, RICTOR’s ortholog studied in Dictyostelium was found to be a
mediator of cell migration and chemotaxis (101). Moreover, multiple in vitro studies
have indicated RICTOR’s role, in conjunction with mTORC2, in cell migration and
cytoskeletal regulation via the phosphorylation of PKCα, paxillin, RhoaA, and Rac1
(41, 102). Moreover, mTORC2 activity is elevated in gliomas, as evidenced by
overexpression of RICTOR in cell lines and primary tumor cells, resulting in enhanced
growth and cellular motility (103). Although most of the functional roles of RICTOR
have been characterized as part of mTORC2, RICTOR carries exclusive independent
roles. For example, RICTOR was shown to form a separate complex with Myo1c,
independent of mTORC2, and participates in cortical actin remodeling events (104).
Recently, insight into the mechanism underlying RICTOR’s regulation of cell migration
and potential contribution to metastasis was elucidated by finding that RICTOR
suppresses RhoGDI2, independently of the mTORC1/2 complexes, promoting the
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activity of the Rho proteins RAC1 and CDC42 (105, 106). Importantly, RhoGDI2 has
been previously implicated as an invasion and metastasis suppressor gene and thus,
its loss has been associated with metastatic cancers (107).
Additionally, RICTOR can interact with integrin-linked kinase (ILK) to increase
AKT phosphorylation and regulate cancer cell survival, and this RICTOR/ILK complex
is also a critical component and mediator of TGFβ-1-induced epithelial-tomesenchymal transition (EMT) in mammary epithelial cells (108, 109). Further, a
kinase-independent function for RICTOR has been proposed through its specific
association with CULLIN-1 and RBX1, forming a functional E3 ubiquitin ligase
complex that promotes SGK1 ubiquitination and degradation, providing a mechanistic
explanation for the high SGK1 expression in various cancers (110, 111). Micro-RNA
(miRNA) regulation of RICTOR has also been reported by linking the overexpression
of RICTOR as a target of miR-218, suggesting that the epigenetic silencing of this
miRNA and subsequent activation of the AKT signaling pathway significantly
contributes to oral carcinogenesis (112). Lastly, RICTOR has been shown to be
required for the development of prostate cancer in the context of PTEN loss, and the
targeting of RICTOR can induce G1 cell cycle arrest and reduction in cyclin D1
expression levels in colon, breast, and prostate cancer cells (113-115). In summary,
RICTOR’s oncogenic role is increasingly becoming evident, as this scaffold molecule
can regulate a multitude of tumorigenic events such as cellular motility, morphology,
cell proliferation, survival, and protein degradation.
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1.9 Hypothesis and specific aims
In summary, the paradigm shift of treatment and diagnosis of lung cancer has
emerged from a single disease entity with limited therapeutic opportunity to one that is
comprised of multiple histotypes, each with its own genomic profile, sparking a
personalized medicinal approach to therapy. Although there are specific examples of
targeted therapies making drastic impact on overall survival of patients with tumors
that are driven by specific oncogenes (e.g. EGFR, ALK, B-RAF), over 30% of lung
adenocarcinomas are still yet to uncover the genetic underpinnings driving these
tumors (Figure 2). In an effort to identify novel potentially actionable targets that
contribute to mechanisms of resistance to targeted therapies, we utilized molecular
profiling data associated with the BATTLE-2 clinical trial, which enrolled advanced
stage chemorefractory NSCLC patients with the goal of evaluating the effects of
targeted therapies based on KRAS-mutated lung tumors (116). Since the majority of
enrolled cases were lung adenocarcinomas, we focused our studies on this lung
cancer subtype and identified a subgroup (17%) of advanced stage patients with
RICTOR genomic alterations (mutations or amplifications). RICTOR’s precise role in
the context of NSCLC has not been extensively evaluated. A recent study classified
RICTOR amplifications as a novel subset of patients with lung cancer that may
respond to dual mTORC1/2 inhibitors (117). To expand on this finding, we were
interested to further define settings where RICTOR or RICTOR-associated signaling
blockade in combination with targeted therapy may enhance response in metastatic
disease and improve outcome.
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Therefore, the proposed hypothesis is that RICTOR alterations promote
oncogenic properties and RICTOR-associated signaling blockade could serve as an
effective therapeutic strategy in KRAS mutant NSCLC.
To pursue this hypothesis, the following specific aims were developed:


Specific Aim 1: To assess the prevalence of RICTOR alterations in
early and advanced stage NSCLC and determine if these alterations
correlate with clinical outcome.



Specific Aim 2: To determine the phenotypic consequences of RICTOR
knockdown in in vitro and in vivo NSCLC models.



Specific Aim 3: To evaluate the potential therapeutic benefit of
RICTOR-associated signaling blockade in pre-clinical NSCLC models.
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Chapter 2
Materials and Methods
Cell lines and reagents
NSCLC cell lines (H23, H2009, H1792, H1650, H3122, H2172, H2126, A549,
HCC44, CALU6, HCC193, and H1819) were either obtained from American Type
Tissue Collection (ATCC, Manassas, VA) or were obtained from collaborators and
authenticated via STR DNA fingerprinting at the University of Texas MD Anderson
Characterized Cell Line Core (CCLC). All cell lines were grown in RPMI 1640
supplemented with 10% FBS (Cellgro, Mediatech, Manassas, VA) with no antibiotics.
Whole genome single nucleotide polymorphism (SNP) array profiling (previously
described (118)) was obtained for the cell line panel to determine RICTOR amplified
(copy number variation (CNV ≥ 3.5) and non-amplified cell lines (CNV = 2).
Immortalized human bronchial epithelial cells (HBEC) expressing wild-type KRAS
(HBEC3-KT) or KRAS-mutant with stable p53 knockdown (HBEC3-KT53KC12) cell
lines were provided by Drs. Adi Gazdar and John Minna (University of Texas
Southwestern Medical Center, Dallas, TX) and maintained in keratinocyte-SFM
medium with bovine pituitary extract and human recombinant epidermal growth factor
(Invitrogen). Generation of stable RICTOR knockdown cell lines were developed
using pTRIPZ inducible lentiviral shRNA-encoding plasmids (RICTOR shRNA
#RHS4696, Non-silencing shRNAmir Control (NTC) #RHS4743) (GE Dharmacon,
Lafayette, Colorado) for the inducible knockdown of RICTOR in the presence of
2μg/mL doxycycline hyclate (SIGMA) and were selected with 2μg/mL puromycin
(SIGMA). RFP expression was also utilized for monitoring transduction and
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knockdown efficiency. Targeted inhibitors AZD2014 (vistusertib), AZD6244
(selumetinib), and GSK1120212 (trametinib) were obtained from Selleck Chemicals
(Houston, TX) and dissolved in DMSO to create stock solutions. All additional
dilutions were performed using the respective cell culture medium for working
concentrations.
Immunoblotting and antibodies
Western blotting analyses were performed on total protein lysates extracted
from NSCLC cell lines. In brief, cell cultures were washed with ice-cold phosphate
buffered saline (1X PBS) containing protease and phosphatase inhibitor tablets
(Roche, Basel, Switzerland) and homogenized in 1X RIPA buffer (SIGMA-Aldrich, St.
Louis, MO). The cells were scraped and samples were centrifuged at 14,000 rpm for
25 minutes at 4C and protein concentrations of supernatants were quantified by DC
Protein Assay per manufacturer’s instructions (Bio-Rad, Hercules, CA). Equal
amounts of protein were separated by pre-cast 4-15% gradient gels (Bio-Rad) via
SDS-PAGE and transferred onto nitrocellulose membranes using the Trans-Blot
Turbo Transfer System (Bio-Rad). Membranes were blocked with 5% milk for 1 hour,
and all washes were in TBS-T. The membranes were incubated with the following
commercial antibodies: RICTOR, p-RICTOR (Thr1135), p-AKT (Ser473), AKT, pMEK1/2 (Ser217/221), MEK1/2, p-p44/42 MAPK (Thr202/Tyr204) (p-ERK1/2),
ERK1/2, c-PARP, PARP, p-mTOR (S2481), mTOR, p-NDRG1 (Thr346), NDRG1,
mSIN1 are from Cell Signaling Technologies (Danvers, MA); β-actin-HRP (used as
equal loading control) and p-PKCα (Ser657) are from Santa Cruz Biotechnology
(Santa Cruz, CA). Secondary antibodies included horseradish peroxidase-conjugated
anti-rabbit or anti-mouse antibodies obtained from Cell Signaling Technologies.
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Immunoreactivity was visualized by use of Western Lightning Plus-ECL (PerkinElmer, Waltham, MA) and exposure to x-ray film according to manufacturer
instructions. Densitometric quantification of bands was performed using Image Studio
Lite 5.0 software (Lincoln, Nebraska).
siRNA knockdown studies
Knockdown studies were performed using ON-TARGETplus SMARTpool
siRNAs targeting the gene of interest at a final concentration of 30 nmol/L using
DharmaFECT I transfection reagent (GE Dharmacon, RNAi Technologies, Thermo).
ON-TARGETplus Non-targeting siRNA pools served as negative controls. siRNAs
were prepared using Opti-MEM I serum free media (ThermoFisher), and added to
culture dishes for 24 hours. Fresh complete media was replaced after 24 hours and
incubation continued for a total of 72-96 hours before downstream analysis.
Cell viability assays
For MTS assay testing cell viability, NSCLC cells were seeded in octuplicate at
a density of 2,000 cells per well in 96-well plates. An endpoint viability assay was
performed using MTS assay (3-4, 5-dimethyl-thiazol-2-yl)-5-(3carboxymethoxyphenyl-2-(4-solfophenyl)-2H-tetrazolium, inner salt) at the indicated
time points according to the manufacturer’s protocol (Promega, Madison, WI). For
experiments evaluating the effect of RICTOR knockdown with mTORC1/2 and/or
MEK1/2 inhibitors, the crystal violet staining and MTT dye reduction method was
used. Stable inducible shRICTOR cell lines were seeded at 2x104 cells per well in 6well plates in the presence of 2μg/mL doxycycline. The next day, each well was
treated with either selumetinib, trametinib, AZD2014, or DMSO (control) at the
30

indicated concentrations and incubation was continued for a further 7 to 10 days, with
drug/media changed every 3 days. MTT solution (Methylthiazolyldiphenyl-tetrazolium
bromide, 1mL per well, 2mg/mL; SIGMA-Aldrich) was added to each well, followed by
incubation for 2-3 hours at 37°C. The media was then removed and the dark blue
crystals in each well were dissolved in 400μL of DMSO and transferred to 96-well
plates. Absorbance was measured at test and reference wavelengths of 550 and 630
nm, respectively, using a FLUOstar Omega microplate reader (BMG LABTECH,
Ortenberg, Germany). The percentage of cell viability is shown relative to untreated
controls.
Cell proliferation assay
Cell proliferation was performed using stably transduced shRICTOR cell lines
(H23, H2009, H1792) by seeding 4x105 cells in 10cm dishes in +/- doxycycline
containing media. Time points were analyzed at 4, 8, 12, and 16 days of continuous
shRICTOR (+doxycycline) treatment to evaluate the effects of RICTOR knockdown.
Total cell number was counted and recorded using the Cellometer K2 Image
Cytometer (Nexcelom, Lawrence, MA). A fixed ratio of cells was subsequently split
into new dishes and sub-cultured for the indicated time points of the experiment.
Cell cycle analysis
For cell cycle analysis, cells were harvested via trypsinization, washed with icecold 1X PBS, and fixed with 70% ice-cold ethanol. Fixed cells were then re-washed,
treated and stained with propidium iodide/RNase using the Propidium Iodide Flow
Cytometry Kit (Abcam, Cambridge, UK) per manufacturer’s protocol. Stained cells
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were immediately analyzed using the BCI Gallios Analyzer flow cytometer (Beckman
Coulter, Brea, CA).
Human p-MAPK Array
A Proteome Profiler Array (Human Phospho-MAPK Array Kit) (R&D Systems,
Inc., Minneapolis, MN) was used to assess the relative level of phosphorylation of 26
kinases involved in the three major families of MAPK pathways. Array was performed
according to manufacturer’s instructions. H23 cells were treated with either NTC or
siRICTOR for 72 hours, and the cells were subjected to lysis using the buffer provided
in the kit. The arrays were then blocked with blocking buffer and incubated with the
cell lysates (300 µg/sample) overnight at 4C. The next day, arrays were washed and
incubated with a biotinylated antibody for 2 hours, washed, and incubated with a
streptavidin-horseradish-peroxidase-conjugated detection antibody, treated with
Western Lightning Plus-ECL, and exposed to x-ray film.
Clonogenic survival assay
NSCLC cells were seeded in 6-well plates (250-500 cells per well) in the
presence or absence of 2μg/mL doxycycline for inducible shRICTOR cell lines or nontargeting control (or siRNA against RICTOR) for 2-3 weeks, with change of media
every 2-3 days. After the endpoint, wells were washed with PBS and fixed with 4%
paraformaldehyde for 10 minutes, followed by staining with 0.05% crystal violet for 30
minutes. Stained wells were then washed thoroughly with water to clear any unbound
crystal violet. Colony area was calculated using Image J software (NIH, Bethesda,
Maryland) to determine percentage area stained relative to control. Soft agar assay
testing anchorage independent growth was performed using Millipore’s Cell
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Transformation Detection Assay per manufacturer’s recommendations (Merck KGaA,
Darmstadt, Germany). In brief, 6-well plates were prepared with 0.8% base agar layer
and allowed to solidify. 2,500 cells/well were resuspended in 0.4% top agar solution
and aliquoted appropriately on top of the base agar layer (pre-warmed to 37C).
Doxycycline containing media was used to induce continuous shRICTOR knockdown
compared to NTC. Cells were incubated for 21-28 days at 37°C until colonies were
formed, with frequent media change every 3 days. Colonies were then visualized with
the accompanied cell stain solution and quantified with the cell quantification solution
by measuring absorbance at 490nm. A well containing only base and top agar layers
without cells served as background control for quantification.
Migration and Invasion assays
The cell migration assay was performed using a 24-well transwell plate with
8μm polyethylene terephthalate (PET) membrane filters (Corning Inc., Corning, NY)
that separate the top and bottom culture chambers. In brief, respective NSCLC cell
lines were transfected with siRNA targeting RICTOR for 72 hours, harvested, and
plated in the upper chamber at a density of 20,000 cells per well in 500μL of 0.5%
reduced serum RPMI 1640 media. The bottom chambers contained 750μL of either
5% serum (serves as chemoattractant) or 0.5% reduced serum conditions. Cells were
allowed to migrate for 24 hours, and filters were then removed and non-migrant cells
on the upper side were wiped away with use of a cotton swab. Filters were fixed and
stained using the Diff-Quik Stain Set Kit (Siemens Healthcare Diagnostics, Newark,
DE) per manufacturer’s protocol and mounted onto microscope slides. Five random
fields were quantified at 10X objective lens in a light microscope, and results are
displayed as the average number of cells migrated. The cell invasion assay was
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similar to the described protocol above, except that the transwell chambers used were
Corning BioCoat Growth Factor Reduced Matrigel invasion chambers and cells were
fixed and stained after 48 hours of incubation.
Xenograft tumor models
All animal procedures and care were approved by the MD Anderson Cancer
Center Institutional Animal Care and Usage Committee. Animals received humane
care as per the Animal Welfare Act and the NIH “Guide for the Care and Use of
Laboratory Animals”. For tumorigenicity studies evaluating the effects of RICTOR
knockdown, H1792 and H23 stable shRICTOR inducible cell lines were expanded and
harvested, washed, and pre-cooled in serum-free RPMI 1640 medium mixed 1:1 with
Corning growth factor reduced Matrigel Matrix (Corning, NY). Female athymic nude
mice, between 6-8 weeks old, were injected subcutaneously in the flank with H1792
(2x106) or H23 (5x106) shRICTOR cells. Mice were divided into two groups with 6
mice per arm: doxycycline feed (600mg/kg; BioServ, Flemington, NJ) immediately
after inoculation of cells, or control group (regular feed). Tumors were measured twice
weekly with a digital caliper, and size was calculated as (length x width2/2). The mice
were euthanized and the tumors were collected for protein lysate analysis. Protein
lysates were prepared by homogenization using the Precellys24 tissue homogenizer
(Bertin Instruments, France).
For studying the effects of drug treatments on xenograft growth, H1792
shRICTOR cells (4x106) were prepared as described above and injected
subcutaneously in the flanks of 6-8 week old female athymic nude mice. After the
average tumor volumes reached 100mm3, mice were randomized into 1 of 5
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treatment arms (6 mice/arm), and the indicated treatment regimens were performed
by oral gavage for 22 days. The treatment arms consisted of: vehicle (1% tween-80,
bid), selumetinib (25mg/kg, bid), selumetinib (25mg/kg, bid) + doxycycline feed
(600mg/kg), AZD2014 (15mg/kg, qd), and selumetinib + AZD2014 (equivalent
dosages used as per individual inhibitor treatments). Selumetinib was obtained from
Selleck Chemicals and AZD2014 was obtained from MedChem Express (Monmouth
Junction, NJ). Tumor volumes and body weights were recorded twice weekly. Tumors
were extracted on the final day 3 hours following the last treatment, and protein
lysates were prepared as described above.
Clinical datasets and patient sample characteristics
A total of 3 datasets were analyzed independently in our study: the Biomarker
Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE-2,
n=92 lung adeno cases with mutation data; n=107 lung adeno cases with mRNA
expression data), The Cancer Genome Atlas (TCGA Lung Adenocarcinoma, n=230
with mutation cases, n=496 with mRNA expression data), and Profiling of Resistance
Patterns and Oncogenic Signaling Pathways in Evaluation of the Thorax
(PROSPECT, n=151). The BATTLE-2 trial is a randomized phase II, multi-center
biopsy-mandated and biomarker-based clinical trial of targeted therapy in advanced
stage chemorefractory NSCLC (116). Clinical and genomic data for 230 mostly earlystage, surgically resected lung adenocarcinomas that were analyzed in the TCGA
dataset was obtained from the cBio Cancer Genomics Portal and GDC data portal
(https://gdc.nci.nih.gov/) (119, 120). The PROSPECT dataset includes surgically
resected tumor tissue collected from patients with lung adenocarcinoma at MD
Anderson Cancer Center. Bioinformatics analyses and support was provided by Dr.
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Jing Wang and Li Shen (Department of Bioinformatics and Computational Biology,
MD Anderson Cancer Center).
Statistical analyses
The results presented are the average of at least two experiments each
performed at least in triplicate. Data obtained from cell culture assays were
summarized using descriptive and inferential statistical analyses accompanied by
graphs and conducted by using GraphPad Prism 6 (GraphPad Software, La Jolla,
CA). Differences between groups were calculated by the t-test unless otherwise
noted. A P-value < 0.05 was considered significant. Cox hazard proportional models
were applied for association between mRNA expression and overall survival.
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Chapter 3
Results
3.1 Identification of RICTOR alterations in advanced NSCLC
NSCLC is biologically and genomically diverse and has differing responses to
standard chemotherapy and targeted therapy developed to inhibit key molecular
aberrations that drive cancer progression. However, over 30% of lung
adenocarcinomas that are diagnosed have alterations that do not have a therapeutic
target. In an effort to identify novel potentially actionable targets in advanced stage
NSCLC, we utilized genomic profiling from an ongoing clinical trial termed the
Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination
(BATTLE-2) as a platform for our studies. The BATTLE-2 was a phase II trial that
specifically targeted advanced stage, chemorefractory NSCLC patients who have
failed at least one prior chemotherapeutic regimen (116). Patients were adaptively
randomized by KRAS status to one of four treatment arms: erlotinib (EGFRi), erlotinib
plus MK2206 (AKTi), MK2206 plus selumetinib (AZD6244; MEKi), or sorafenib
(RAFi/VEGFRi) (Figure 6). Prospective biopsies based on specified tumor markers
were utilized for adaptive randomization to assign patients to the treatment arm with
the most potential benefit on the basis of cumulative data at the time. Molecular
profiling was performed on all acquired biopsies via the FoundationOne hybridization
capture-based next-generation sequencing (NGS) test which evaluated over 182
cancer-related genes (Foundation Medicine, Inc.).
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Figure 6. Identifying novel actionable targets in refractory NSCLC using the
BATTLE-2 clinical trial. The Biomarker-Integrated Approaches of Targeted Therapy
for Lung Cancer Elimination (BATTLE-2) is a phase II trial that specifically targets
advanced stage, chemorefractory KRAS mutated NSCLC patients that have failed at
least one prior chemotherapeutic regimen. Exclusion criteria included tumors with
sensitizing EGFR mutations or ALK gene fusions if they had not been previously
treated with erlotinib or crizotinib. Patients agree to a baseline tumor biopsy (for
biomarker analysis) and were adaptively randomized by KRAS status to one of four
treatment arms: erlotinib (EGFRi), erlotinib plus MK2206 (AKTi), MK2206 plus
selumetinib (AZD6244, MEKi), or sorafenib (RAFi, VEGFRi). The primary endpoint
was 8-week disease control rate based on Response Evaluation Criteria in Solid
Tumors (RECIST). The specific nodes of the pathways targeted are illustrated.
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The detailed protocol and analysis of the NGS assay has been previously reported
(121). The frequency of selected genes identified from the NGS targeted panel that
carry mutations and/or amplifications are shown in Figure 7, which includes the entire
NSCLC BATTLE-2 cases sequenced. The criteria used to identify potentially
actionable targets were to first identify genes that were amplified or mutated, followed
by if they were targetable. We focused our attention on RICTOR alterations as they
have not been extensively studied in the context of NSCLC and are present at a
relatively high frequency, suggesting possible actionability.

Figure 7. Frequency of potentially actionable genes that carry mutations and/or
amplifications from the NGS FoundationOne targeted panel. The percentage
shown is out of 159 NSCLC cases that have mutation/copy number alteration data.
Frequently altered genes, such as KRAS and EGFR, were excluded from this graph
since these were not novel targets. Genes are listed in Abbreviations section. The
frequency of RICTOR gene alterations (~13.2%, 21/159) is highlighted in blue.
Moreover, we filtered our studies to lung adenocarcinoma cases since the
majority of the enrolled patient population in the BATTLE-2 trial were of this NSCLC
subtype. A total of 92 chemorefractory lung adenocarcinoma tumor biopsies have
undergone NGS profiling. We identified RICTOR gene alterations in a total of 17.4%
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(16/92) of cases, including 11.9% amplifications (11/92) and 5.4% mutations (5/92),
which were mutually exclusive (Figure 8A, left).

A)

B)

Figure 8. RICTOR alterations are present in early and advanced stage lung
adenocarcinomas at similar frequencies. (A) Summary of frequency of RICTOR
gene alterations (mutations or amplifications) in chemorefractory advanced lung
adenocarcinoma samples (BATTLE-2, n=92) and in early stage lung adenocarcinoma
samples (TCGA, n=230) (8). (B) Schematic of novel RICTOR gene mutations from the
BATTLE-2 NSCLC cohort and number of mutant cases.
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Mutations in the RICTOR gene have not been previously identified, particularly the
functional roles of these mutations. Figure 8B illustrates the location along the
RICTOR gene in which these novel mutations occur. The significance of these
RICTOR mutations are yet to be determined, as the crystal structure of RICTOR has
not been elucidated and current bioinformatics tools have failed to identify functional
domains of this scaffold protein. However, a recent study attempted to shed light into
RICTOR’s poorly understood domain architecture by searching for conserved regions
to assign structural and functional domains (122). The study identified that similar to
its counterpart RAPTOR, RICTOR also has HEAT, WD40, and PH domains that might
be utilized for common motif binding to mTORC, mediating cellular localization and
transmission of signaling to downstream effectors. Although this is the first such report
analyzing RICTOR’s domain structure, experimental confirmation is still needed to
validate these findings.
Furthermore, to determine whether RICTOR alterations are an early event in
lung cancer progression, we surveyed the frequency of alterations in early stage lung
adenocarcinoma cases utilizing The Cancer Genome Atlas (TCGA) database (120,
123). We identified a similar frequency of a total 13.4% (31/230) of RICTOR-altered
cases, which included 10% amplifications (25/230) and 5.2% mutations (12/230).
Interestingly, in contrast to the BATTLE-2 advanced stage tumors, some early stage
tumors from the TCGA incurred concomitant amplifications and mutations (Fig. 8A,
right). In addition, in surveying the frequency of RICTOR alterations across various
cancer types, we found the highest prevalence of alterations in NSCLC, particularly
lung adenocarcinoma, compared to other reported tumor types (Figure 9).
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Figure 9. Cross-cancer mutational frequency of RICTOR in the TCGA
database. cBioPortal query across various cancer types for RICTOR DNA
mutation frequencies. Alteration frequency is displayed as a histogram across
reported cancer studies. NSCLC datasets are marked with an asterisk, showing
lung adenocarcinoma as the most frequently mutated tumor type. Database
accessed on November 18, 2016.
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3.2 RICTOR mRNA expression is higher in RICTOR amplified than non-amplified
NSCLC
We next evaluated the correlation between RICTOR amplification and RICTOR
gene expression in our two datasets. There was a significant direct correlation
between RICTOR gene amplification and RICTOR mRNA expression in the early
stage TCGA dataset, and a trend seen in the advanced stage BATTLE-2 lung
adenocarcinoma cases (Figure 10). Of note, when we performed this analysis
including all NSCLC subtypes from the BATTLE-2 cases (total of 159 cases with DNA
NGS profiling), there was statistical significance of direct correlation between RICTOR
gene amplification and RICTOR mRNA expression (data not shown), suggesting that
the sample size in the BATTLE-2 adenocarcinoma was too small to reach statistical
significance.

Figure 10. Correlation of RICTOR amplification to mRNA gene expression in
lung adenocarcinoma cases. Correlation of RICTOR amplified vs. non-amplified
cases to RICTOR mRNA (log2) expression levels in BATTLE-2 (n=92) (left) and
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TCGA (n=230) (right) datasets. Red circle = amplified RICTOR case; blue circle =
non-amplified RICTOR case.
3.3 Associating RICTOR mRNA expression to clinical outcome
To determine the association of RICTOR alterations to clinical outcome, we
performed a univariate overall survival (OS) analysis of RICTOR mRNA expression in
lung adenocarcinoma patients using the Cox proportional hazards model. As shown in
Table 1, there is significantly worse overall survival in patients with advanced stage
lung adenocarcinoma in the BATTLE-2 cases (OS, hazard ratio [HR]: 1.73, 95%
confidence interval [CI]: 1.23-2.42, P=0.0015). We also saw a worse prognosis in our
early stage surgically resected lung adenocarcinoma cases from the PROSPECT
dataset (OS, HR: 1.54, 95% CI: 1.03-2.29, P=0.0337); however, no significance was
seen in patients from the TCGA dataset.

Table 1. Univariate overall survival analysis of RICTOR mRNA expression in
lung adenocarcinoma patients by Cox proportional hazards model
Study

HR (95% CI)

P-value

BATTLE-2 Trial (n=107)

1.73 (1.23-2.42)

0.0015

PROSPECT (n=151)

1.54 (1.03-2.29)

0.0337

TCGA (n=496)

1.05 (0.81-1.37)

0.675

Abbreviations: HR, hazard ratio; CI, confidence interval.

3.4 Surveying the co-mutational landscape of RICTOR alterations
We next explored the co-mutational landscape of RICTOR-altered cases using
the TCGA lung adenocarcinoma dataset to determine enrichment of specific pathway
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alterations that are known to be aberrantly regulated in lung cancers. We surveyed
the percent alterations (mutations and/or copy number changes) in several key genes
that play important roles in mediating pathways such as receptor tyrosine kinase
(RTK) signaling, mTOR signaling, MAPK signaling, and oxidative stress response.
The specific gene alterations and frequencies are listed in Table 2. As depicted in
Figure 11, there were significantly higher PTEN co-mutant cases in the RICTORaltered group, suggestive of a hyperactive PI3K/RICTOR/AKT pathway. Interestingly,
there was mutual exclusivity between RICTOR alterations and STK11 mutations in
both the TCGA and BATTLE-2 datasets. We found an enrichment of alterations
(mutations and/or amplifications) in several key genes of the MAPK pathway in
RICTOR-altered cases compared to the rest. There was a notably high percentage of
KRAS, NF1, BRAF/CRAF alterations in the RICTOR-altered cases. These data
suggest that RICTOR expression could be an important co-oncogenic driver in lung
cancer progression, and thus we focused our efforts on characterizing the importance
of RICTOR, specifically in KRAS mutant settings.
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Figure 11. Surveying the co-mutational landscape of RICTOR-altered cases.
Selected pathways are shown with percentages of gene alterations (mutations and/or
copy number changes) extracted from the lung adenocarcinoma dataset of the
cBioPortal for Cancer Genomics. The percentages of gene alterations in RICTORaltered cases (outside parenthesis) are compared to non-altered cases (inside
parenthesis).
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Table 2. List of co-mutant genes and their frequency of alterations (TCGA LuAd)
Gene

EGFR

Type
of Alt

# in RICTOR
alt (%)
(out of 31)

# in RICTOR
un-alt (%)
(out of 199)

Log
ratio

p-value

q-value

Tendency

mut

4 (12.9%)

29 (14.57%)

-0.18

0.531

0.865

Mut exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mut exclusivity

amp

3 (9.68%)

12 (6.03%)

0.68

0.328

0.801

Co-occurrence

mut

2 (6.45%)

4 (2.01%)

1.68

0.187

0.733

Co-occurrence

amp

1 (3.23%)

5 (2.51%)

0.36

0.585

0.865

Co-occurrence

mut

1 (3.23%)

18 (9.05%)

-1.49

0.24

0.733

Mutual exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

amp

3 (9.68%)

5 (2.51%)

1.95

0.0777

0.629

Co-occurrence

mut

3 (9.68%)

15 (7.54%)

0.36

0.448

0.865

Co-occurrence

mut

1 (3.23%)

8 (4.02%)

-0.32

0.652

0.865

Mutual exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

mut

3 (9.68%)

9 (4.52%)

1.1

0.209

0.733

Co-occurrence

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

mut

8 (25.81%)

67 (33.67%)

-0.38

0.257

0.748

Mutual exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

amp

1 (3.23%)

12 (6.03%)

-0.9

0.455

0.865

Mutual exclusivity

mut

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

del

0 (0.00%)

4 (2.01%)

<-10

0.558

0.865

Mutual exclusivity

amp

1 (3.23%)

1 (0.50%)

2.68

0.252

0.703

Co-occurrence

mut

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

mut

0 (0.00%)

5 (2.51%)

<-10

0.482

0.865

Mutual exclusivity

amp

5 (16.13%)

27 (13.57%)

0.25

0.439

0.865

Co-occurrence

mut

9 (29.03%)

18 (9.05%)

1.68

3.93E-03

0.324

Co-occurrence

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

ERBB2

MET

ALK

RET

ROS1

KRAS

NRAS

HRAS

RIT1

NF1
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amp

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

mut

4 (12.90%)

18 (9.05%)

0.51

0.342

0.83

Co-occurrence

amp

3 (9.68%)

3 (1.51%)

2.68

0.0336

0.475

Co-occurrence

mut

1 (3.23%)

1 (0.50%)

2.68

0.252

0.733

Co-occurrence

mut

0 (0.00%)

3 (1.51%)

<-10

0.646

0.865

Mutual exclusivity

amp

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

mut

4 (12.90%)

36 (18.09%)

-0.49

0.338

0.83

Mutual exclusivity

del

0 (0.00%)

4 (2.01%)

<-10

0.558

0.865

Mutual exclusivity

mut

1 (3.23%)

3 (1.51%)

1.1

0.442

0.865

Co-occurrence

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

amp

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

mut

0 (0.00%)

4 (2.01%)

<-10

0.558

0.865

Mutual exclusivity

amp

1 (3.23%)

5 (2.51%)

0.36

0.585

0.865

Co-occurrence

mut

2 (6.45%)

1 (0.50%)

3.68

0.0485

0.612

Co-occurrence

amp

2 (6.45%)

2 (1.01%)

2.68

0.0888

0.629

Co-occurrence

mut

0 (0.00%)

2 (1.01%)

<-10

0.748

0.865

Mutual exclusivity

del

0 (0.00%)

3 (1.51%)

<-10

0.646

0.865

Mutual exclusivity

mut

1 (3.23%)

14 (7.04%)

-1.12

0.372

0.863

Mutual exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

amp

2 (6.45%)

3 (1.51%)

2.1

0.136

0.629

Co-occurrence

mut

0 (0.00%)

2 (1.01%)

<-10

0.748

0.865

Mutual exclusivity

del

0 (0.00%)

1 (0.50%)

<-10

0.865

0.865

Mutual exclusivity

amp

0 (0.00%)

2 (1.01%)

<-10

0.748

0.865

Mutual exclusivity

mut

0 (0.00%)

40 (20.10%)

<-10

1.67E-03

0.262

Mutual exclusivity

del

0 (0.00%)

3 (1.51%)

<-10

0.646

0.865

Mutual exclusivity

BRAF

RAF1

MAP2K1

KEAP1

CUL3

NFE2L2

PTEN

PIK3R1

PIK3CA

AKT1

STK11

TCGA cBioPortal calculates Log ratio = Log2 based ratio of (% in altered / % in unaltered);
p-value derived from Fisher Exact Test; q-value derived from Benjamini-Hochberg procedure.
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Chapter 4
Results
4.1 Selection and mutational background of RICTOR cell line panel
In order to study the oncogenic effects imposed by RICTOR, we established a
RICTOR cell line panel by first screening 57 NSCLC cell lines to detect RICTOR copy
number variations (CNVs) by utilizing a single nucleotide polymorphism (SNP) array
(Figure 12). We selected seven RICTOR amplified (highlighted in red arrows) and five
non-amplified cell lines (highlighted in black arrows) that span diverse co-mutational
backgrounds, including several lines that harbor KRAS, PTEN, PIK3CA, STK11,
and/or EGFR mutations. The mutational background of the cell line panel used in our
studies is summarized in Table 3. RICTOR amplified cell lines chosen were H23,
H3122, H1792, H2009, H1650, H2172, H2126 and non-amplified cell lines were
HCC193, H1819, A549, CALU6, and HCC44.
Moreover, in order to perform experiments that require extended duration for
completion, we established several stable inducible shRICTOR cell line models
(Figure 13). These cell lines possess puromycin resistance and inducible red
fluorescence protein (RFP) expression for selection and visualization of transduction
efficiency, respectively. Upon administration of doxycycline, we see a significant
reduction in the RICTOR protein expression levels in the selected cell lines.
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Figure 12. Selection of RICTOR cell line panel used for in vitro studies. Whole
genome single nucleotide polymorphism (SNP) array profiling was obtained for 57
NSCLC cell lines to determine RICTOR amplified (copy number variation (CNV ≥ 3.5)
and non-amplified cell lines (CNV ~2). Seven RICTOR amplified cell lines (red arrows)
and five RICTOR-non-amplified cell lines (black arrows) were selected. Copy number
variation (CNV) values: red = amplified; black = diploid; green = deletion.

Figure 13. Establishment of inducible shRICTOR cell line models. Several cell
lines from the RICTOR cell line panel were used to establish tet-ON inducible
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shRICTOR cell line models. pTRIPZ plasmid (Dharmacon) was used to stably
transduce the indicated cell lines, and puromycin and RFP was used for positive clone
selection. Doxycycline was used to stably knock down RICTOR in the cells, following
dose and time optimization. Ideal knockdown was seen after doxycycline
administration (2 µg/mL) for 96-144 hours depending on the cell line. Non-targeting
control (NTC) was used as a doxycycline and transduction negative control, and βactin used as a loading control for Western blotting.

RICTOR
non-amplified

RICTOR amplified

Table 3. Mutational profile of RICTOR NSCLC cell line panel.

Cell line

KRAS

EGFR STK11 PIK3CA PTEN EML4/ALK

H2172

WT

WT

WT

WT

WT

WT

H2126

WT

WT

Mut

WT

WT

WT

H23

mut - G12C

WT

Mut

WT

Mut

WT

H3122

WT

WT

WT

WT

WT

Mut

H1792 mut - G12C

WT

WT

WT

WT

WT

H1650

WT

Mut

WT

Mut

Mut

WT

H2009

mut - G12A

WT

WT

WT

WT

WT

HCC193

WT

WT

WT

WT

WT

WT

H1819

WT

WT

WT

WT

WT

WT

A549

mut - G12S

WT

Mut

WT

WT

WT

Calu6

mut - Q61K

WT

WT

WT

WT

WT

HCC44 mut - G12C

WT

Mut

WT

WT

WT
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4.2 RICTOR signaling in RICTOR amplified versus non-amplified cell lines
After selecting our cell lines that carry additional secondary mutations,
representative of the complex heterogeneity of NSCLC, we wanted to assess the
signaling patterns associated with these cells at basal level. Figure 14 shows western
blotting analysis of the signaling patterns seen in the amplified (shown in red) versus
the non-amplified (shown in black) cell lines. We noticed several key

Figure 14. Comparison of signaling and RICTOR expression in amplified versus
non-amplified cell lines. (Left) Cell lysates from 12 NSCLC cell lines (amplified or
non-amplified for RICTOR) were examined by Western blotting. Total and phosphospecific antibodies used were for levels of RICTOR, mSIN1, p-AKT (S473), AKT, pPKCα (S657), p-NDRG1 (T346), NDRG1, p-mTOR (S2481), mTOR, and β-Actin as
loading control. (Right) Quantification of relative RICTOR/β-Actin protein expression
from densitometric analysis of western blot panel. *, P = 0.01.
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trends that became apparent. First, RICTOR protein expression was significantly
higher in the RICTOR amplified cell lines compared to the non-amplified cell lines.
Densitometric analysis of relative RICTOR/β-Actin protein expression from the
Western blot is shown on the right, and shows significantly higher RICTOR protein
expression (*, P = 0.01). This is in concordance with our clinical analysis data from
the TCGA and BATTLE-2 cohorts, showing that RICTOR amplification directly
correlates with an overall higher RICTOR mRNA expression, suggesting that
amplification of this gene drives the overexpression of the protein product. Next, we
discovered that the expression of the mTORC2 component, mSIN1, is elevated in
RICTOR amplified cells, suggesting increased rate of mTORC2 complex formation
and potential activity (124). Additionally, increased mTORC2 activity markers were
seen in our amplified cells, marked by an overall increase in p-PKCα S657 levels and
elevated phosphorylation of N-myc downstream regulated gene 1 (p-NDRG1 T346),
which serves as a surrogate marker for SGK1 activity (43). Interestingly, although
mTORC2 is predominately responsible for the phosphorylation of AKT on S473
leading to full activation, our RICTOR amplified cell lines displayed variable degrees
of basal AKT activity levels compared to our non-amplified cells. This could be
attributed to the complex heterogeneity of these cell lines that induce signaling to the
often-deregulated PI3K/AKT/mTOR pathway. Also, other AKT regulators have been
shown to influence AKT activation such as DNA-dependent protein kinase (DNA-PK),
ILK1, protein kinase CβII (PKCβII), PH domain leucine-rich repeat protein
phosphatase (PHLPP), and ataxia-telangiectasia mutant (ATM), all shown to reflect
the various cellular contexts in which AKT activity may be modulated (26, 125, 126).
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4.3 RICTOR knockdown decreases colony formation and anchorageindependent growth in amplified cells
We next sought to determine the phenotypic consequences of RICTOR
knockdown in vitro. We utilized our established stably transduced doxycycline (doxy)inducible shRICTOR cell lines that are either amplified or not for RICTOR. Following
RICTOR knockdown in our cell lines, colony formation potential was assessed after 2
to 3 weeks and resulted in a significant reduction of colony growth in all 3 of our
RICTOR amplified cell lines (H23, H2009, H1792), as measured by relative
percentage of colony area compared to non-targeting control (NTC) (*, P < 0.05)
(Figure 15, top). We did not see an effect in our non-amplified cell lines A549 and
HCC193, suggesting that RICTOR amplifications provide a survival advantage to
NSCLC cells driven by increased RICTOR expression. Additionally, when we
performed an anchorage-independent growth assay to test the transformative ability
of RICTOR by plating H23 cells on soft agarose and treating either NTC or shRICTOR
cells with doxycycline to stably knock down RICTOR, there was complete abrogation
of colony formation following RICTOR inhibition, again suggesting that RICTOR
contributes proliferative properties to cells (Figure 15, bottom).
4.4 RICTOR knockdown decreases cell proliferation in part through G0/G1 cell
cycle arrest
Since we witnessed a dramatic reduction in the colony formation potential of
cells following RICTOR knockdown, it was of interest to determine the precise role
that RICTOR plays in regulating cell survival and/or proliferation. We therefore
performed a cell proliferation assay by culturing cells in the presence or absence of
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Figure 15. RICTOR knockdown decreases colony formation and anchorageindependent growth in amplified cells. (Top) Colony formation assay of 3 RICTOR
amplified cell lines (H23, H2009, H1792) and 2 non-amplified cell lines (A549,
HCC193) comparing RICTOR knockdown to non-targeting control. Data are graphed
as the mean percentage ± percent SD. (Bottom) Anchorage-independent growth
assay in soft agar of stably transduced H23 cell line with RICTOR knockdown (A549
serves as positive control). *, P < 0.05; n.s. = not significant.

55

doxycycline to induce RICTOR knockdown for an extended duration of time, and
quantified total cell numbers at 4, 8, 12, and 16 days of incubation (Figure 16A).
Results demonstrate that reducing RICTOR levels in the three cell lines tested
markedly reduced the total cell numbers in as early as 4 to 8 days, and reduced the
cell numbers by over 75% in all 3 cell types by day 16, yielding similar results to the
colony formation assay (Figure 15). Moreover, we assessed whether this reduction in
cell number was due to cell cycle changes. H23, H2009, and H1792 cell lines were
cultured for 8 days with or without doxycycline, and stained with Propidium iodide (PI)
for FACS cell cycle analysis. As seen in Figure 16B, RICTOR knockdown resulted in
a slight G0/G1 cell cycle arrest in all 3 cell lines tested. Quantification of the cell cycle
phases was performed and shows an increase of 10%, 11.7%, 4.9% G0/G1 cell cycle
arrest in the shRICTOR cells compared to NTC cells of H23, H1792, and H2009,
respectively (Figure 16C). Previous reports have linked RICTOR/mTORC2 to the
regulation of the cell cycle through modulation of cyclin-D1 levels (115, 127-129). To
test this, we performed Western blotting analysis on the H23 cell line to check for pAKT, p-MEK1/2, and cyclin-D1 levels (Figure 16D) following RICTOR knockdown via
siRNA. We witnessed a slight decrease in the levels of Cyclin-D1 following RICTOR
siRNA, providing a potential explanation of the modest increase seen in the G0/G1 cell
cycle arrest.
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D

Figure 16. RICTOR knockdown decreases the cell proliferative capacity. (A)
Quantification of the relative cell number counts of shRICTOR cells relative to NTC
cells at the indicated time points following doxycycline treatment. Complete cell
counts were performed following 4, 8, 12, 16 days of incubation and shown as
percentage relative to NTC. (B, C) Flow cytometry histograms and quantification of
the phases of cell cycle in NTC versus shRICTOR cells following Propidium iodide
(PI) staining and FACS sorting after 8 days of incubation. (D) Western blotting
analysis of representative H23 cell line showing decreased cyclin-D1 expression.

57

4.5 RICTOR knockdown reduces the migration and invasion capacity of RICTOR
amplified NSCLC cells
To determine whether RICTOR plays a role in mediating migration and
invasion of NSCLC cells, we utilized transwell in vitro migration and invasion assay
chambers. These assays allow for the quantification of migratory and invasive cells
that are able to move through specified pores of a filter membrane chamber placed in
media containing a chemoattractant (e.g. FBS). After the cells were incubated for 24
hours, the number of H23, H2009, and H1792 cells (RICTOR amplified, KRAS mutant
cell lines) that migrated through the membranes of the chambers were significantly
lower following RICTOR knockdown (>50%) in both serum reduced and normal serum
conditions (P ≤ 0.001) compared to NTC cells (Figure 17, top). Interestingly, H2172
and H2126 (RICTOR amplified, KRAS wild-type cell lines) had a very poor basal
migrative capacity, seen by the number of migratory control (NTC) cells quantified
even in the absence of RICTOR knockdown (Figure 17, bottom). The results indicate
that RICTOR knockdown reduces the migratory capability of RICTOR amplified
NSCLC cell lines that possess KRAS co-mutations.
Similarly, the invasive capability was assessed using a Matrigel coated
membrane filter chamber. After incubation of cells for 48 hours in either serum
reduced or normal serum conditions, the number of cells that invaded through the
membranous matrix were quantified. As seen in Figure 18 (top), H23, H2009, and
H1792 cells had a significant reduction in the number of invasive cells following
siRICTOR compared to NTC in both serum reduced and full serum conditions (P ≤
0.001). H2009 had the most dramatic reduction in invasive ability (>80%) followed by
H23 (>61%) and H1792 (>44%). Of note, similar to the migrative capacities, the
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RICTOR amplified KRAS wild-type cell lines H2172 and H2126 had a very poor basal
invasive capability, once again emphasizing the potential importance of mutant KRAS
perhaps serving as a co-oncogenic driver with RICTOR to fuel these tumorigenic
properties in these cell types. Taken together, these results show that RICTOR
knockdown suppresses the migration and invasion efficiency of select NSCLC cell
types.
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Figure 17. RICTOR knockdown reduces migration potential in RICTOR
amplified cell lines. Cell migration was assessed using transwell chambers with
8μm pore polyethylene terephthalate (PET) membrane filters. Cells were incubated
in either reduced serum (0.5%) or normal serum (5%) for 24 hours. Representative
visual images of the stained surfaces are shown. The results presented are an
average of five random microscopic fields at 10X of the number of cells stained and
counted. Data shown are of the means ± standard error of the means (SEM) of data
from at least 3 independent experiments. *P = 0.001; **P < 0.001.
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Figure 18. RICTOR knockdown reduces invasion potential in RICTOR amplified
cell lines. Cell invasion was assessed using modified transwell chambers coated
with growth factor reduced Matrigel with 8μm pore polyethylene terephthalate (PET)
membrane filters. Cells were incubated in either reduced serum (0.5%) or normal
serum (5%) for 48 hours. Representative visual images of the stained surfaces are
shown. The results presented are an average of five random microscopic fields at
10X of the number of cells stained and counted. Data shown are of the means ±
standard error of the means (SEM) of data from at least 3 independent experiments.
*P < 0.01; **P < 0.001; ns=not significant.

61

4.6 RICTOR knockdown results in reduced tumorigenicity in vivo
Our data thus far suggests that RICTOR serves as an important oncogene
involved in promoting various malignant phenotypes such as colony formation,
migration and invasion. We wanted to investigate the role of RICTOR in vivo by use of
murine xenografts engrafted with our established inducible shRICTOR lung
adenocarcinoma cell lines H1792 and H23. There was a significant reduction in
H1792 and H23 xenograft tumor growth following continuous induction of RICTOR
knockdown by doxycycline administration compared to mouse control groups without
treatment by 6 weeks (*, P < 0.05) (Figure 19 A, B). To assess the molecular
signaling patterns following RICTOR blockade in vivo, we extracted total protein
lysates from the tumor tissues of both the doxycycline treated and control groups from
H1792 xenografts and performed Western blotting analysis. As seen in Figure 19C,
RICTOR expression was significantly reduced in the +Doxy group and resulted in
overall decreased p-AKT levels, in concordance with our in vitro results. In addition, pMEK1/2 and p-ERK1/2 levels were elevated in the RICTOR knockdown tumors,
indicative of the compensatory mechanisms seen in vitro in our KRAS mutant cell
lines. Taken together, genetic blockade of RICTOR is associated with growth
inhibition in vivo, further supporting RICTOR’s role as an oncogenic driver in NSCLC.
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Figure 19. RICTOR knockdown using RICTOR shRNA results in reduced
tumorigenicity in vivo. (A, B) Athymic nude mice were inoculated with H1792 or
H23 shRICTOR cell lines and were fed with either doxycycline (+Doxy, 600mg/kg) or
control diet (-Doxy). Tumor volumes were measured twice weekly. Data points are
presented as the mean tumor volume ± SEM. Representative images of xenograft
tumors from each group before tumor harvesting are shown. *, P = 0.01; **, P < 0.01.
(C) Lysates extracted from H1792 tumor xenografts were subjected to Western blot
analysis with the indicated antibodies, showing RICTOR knockdown.
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Chapter 5
Results
5.1 Compensatory MAPK signaling activation following RICTOR inhibition in
KRAS mutant settings
Our clinical analysis of RICTOR-altered cases from the TCGA dataset
demonstrated an enrichment of MAPK pathway alterations (Figure 11). Thus, we
wanted to determine possible changes in the cell signaling patterns of the
RAS/RAF/MEK pathway affected by RICTOR. We performed knockdown studies via
siRNA in several cell lines from our panel that harbor either RICTOR amplifications
and/or KRAS mutations. Western blot analysis indicated that RICTOR siRNA
effectively knocked down RICTOR protein expression levels in the respective samples
(Figure 20A). Interestingly, siRICTOR treatment in RICTOR amplified NSCLC cell
lines that harbor KRAS mutations (H23, H2009, H1792) resulted in a compensatory
increased activation of the MAPK pathway seen by elevated levels of phosphorylated
MEK (p-MEK1/2) compared to non-targeting control (NTC) treatment (Figure 20A). As
expected, we saw a reduction in the full activation of AKT S473 (p-AKT) in these cells
after RICTOR knockdown, associated with reduced mTORC2 activity. To determine if
this compensation occurs specifically in KRAS mutant settings, we performed
siRICTOR treatment on RICTOR amplified but KRAS wild-type cell lines (H1650,
H2126, H2172), and results confirmed there was no significant increase in the pMEK1/2 levels. Of note, p-AKT levels were not reduced following RICTOR inhibition in
H1650 (EGFR, PIK3CA, PTEN mutant) and H2126 (LKB1 mutant), which could be a
result of their secondary mutations known to stimulate the PI3K/AKT/mTOR pathway.
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Interestingly, a similar compensatory MAPK pathway activation was seen in RICTOR
non-amplified but KRAS mutant cell lines (A549, HCC44), but not in KRAS wild-type
cell lines (H1819, HCC193), suggesting that RICTOR amplification is not necessary
for driving this compensatory mechanism.
To further test our hypothesis that mutant KRAS is important in mediating this
compensatory mechanism following RICTOR blockade, we performed double
knockdown studies via siRNA targeting RICTOR and KRAS alone, or in combination.
As seen in Figure 20B, in two of our RICTOR amplified KRAS mutant cell lines (H23,
H1792), Western blotting results of siRICTOR showed an elevated activation of pMEK1/2, whereas siKRAS alone actually reduced the p-MEK1/2 levels and hence
decreased MAPK pathway activity. When concomitant targeting of siRICTOR and
siKRAS occurred, there was no increase in p-MEK1/2 levels, suggesting that there is
an important interplay between RICTOR and mutant KRAS. Collectively, these
findings suggest that there is a fine tuned balance of pro-survival signaling
mechanisms in RICTOR/KRAS-altered settings, such that when the RICTOR pathway
is blocked the cells tip the pro-survival balance to the parallel oncogenic MAPK
pathway mediated by mutant KRAS, through increased activation of p-MEK1/2
(Figure 20C). These data expose a unique therapeutic vulnerability in this specific
setting where dual pathway targeted therapy approaches could be beneficial.
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Figure 20. Compensatory MAPK signaling activation following RICTOR
knockdown in KRAS mutant settings. (A) A panel of 6 RICTOR amplified and 4 nonamplified NSCLC cell lines that are KRAS wildtype or mutant were transfected with
siRNAs specific for RICTOR or scrambled negative control for 72 hours and cell
lysates were analyzed by Western blotting for the specified proteins. (B) H23 and
H1792 cells were transfected with siRNAs specific for RICTOR, KRAS, or scrambled
negative control for 72 hours and cell lysates were analyzed by Western blotting for
the specified proteins. (C) Potential model of compensatory mechanism between
RICTOR and mutant KRAS.
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5.2 Compensatory MEK1/2 activation following RICTOR knockdown may be
mediated through de-repression of inhibitory CRAF phosphorylation
We next wanted to elucidate a potential mechanism behind the compensatory
upregulation of p-MEK1/2, which occurs following RICTOR inhibition. We treated our
H23 cell line (RICTOR amplified, KRAS mutant) with either siRNA directed against
RICTOR or various mTOR/MAPK pathway inhibitors targeting mTORC1 (everolimus),
mTORC1/2 (AZD2014), MEK1/2 (AZD6244, selumetinib), or a combination of
AZD2014 and AZD6244 (Figure 21A). Whole-cell lysates were then extracted and
probed with phosphorylation-specific antibodies for various PI3K/AKT/mTOR and
MAPK pathway activation markers and Western blotting analysis was performed. In
first assessing the full activation of AKT (p-AKT S473) under the different treatment
conditions, siRICTOR treatment reduced the p-AKT levels as expected, with similar
results seen after treatment with the dual mTORC1/2 inhibitor, AZD2014. Treatment
with the mTORC1 inhibitor everolimus, however, increased the activity of AKT as
previously reported (130, 131), most likely through attenuation of upstream feedback
inhibition of IGF-1 receptor. To further confirm the specificity of the drugs and the
subsequent downregulation of mTORC1 pathway activity, the p-S6RP levels were
measured and were shown to be completely inhibited with everolimus or AZD2014
treatment, but unchanged with the selective MEK1/2 inhibitor AZD6244, confirming
that each drug was working selectively and inhibiting its respective pathway.
Additionally, to reconfirm the compensatory activation of p-MEK1/2 after
RICTOR inhibition, treatment of H23 cells with siRICTOR significantly increased the
p-MEK1/2 levels compared to parental or NTC cells, as previously shown (Figure
20A, B). Moreover, when AZD6244 was used to block MEK1/2 signaling, we saw a
67

significant reduction in the downstream p-ERK1/2 levels, reinforcing the specificity
and downregulation of the MAPK pathway activity with this drug. Expectedly, there
was also a dramatic increase in the p-MEK1/2 levels, as previously reported (132,
133). This is because selumetinib does not disrupt the phosphorylated activation loop
sites of MEK1/2, and therefore, treatment with this MEK inhibitor relieves a negative
feedback loop mediated through ERK1/2. When p-ERK1/2 levels decrease, the relief
of the feedback loop allows stronger activation of upstream components and
ultimately reactivates phosphorylated MEK1/2 levels.
Moreover, we evaluated the effects of the treatments on the levels of p-CRAF
S259, a site previously reported to be an inhibitory phosphorylation mediated directly
by AKT (49, 54, 55). Our hypothesis was that the compensatory activation of pMEK1/2 following RICTOR knockdown is mediated through de-repression of the
inhibitory CRAF phosphorylation as a result of decreased activation of AKT, leading to
a more active CRAF involved in transduction of mutant KRAS signaling (Figure 21A).
A proposed model of this interaction is illustrated in Figure 21C. Densitometric
quantification of p-CRAF shows that siRICTOR decreased p-CRAF S259 by an
average of 34% compared to parental and NTC H23 cells (Figure 21B). Conversely,
the specific mTORC1 inhibitor, everolimus, did not yield a significant reduction, likely
due to the hyperactivation of p-AKT; however, the combination of everolimus with
siRICTOR had an average 43% reduction of p-CRAF S259, similar to siRICTOR
alone. Interestingly, treatment with the dual mTORC1/2 inhibitor, AZD2014, only
decreased the p-CRAF levels by an average of 23%. This could suggest that RICTOR
may have a more important interplay with AKT, independent of its interaction with
mTORC2, in modulating AKT activity and ultimately regulating CRAF activation
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through mutant KRAS. Alternatively, the lower reduction of p-CRAF seen by AZD2014
could be due to the specificity of AZD2014’s inhibitory mechanism on the mTOR
kinase directly, and not RICTOR, suggesting that there is a unique and specific
interplay between RICTOR and KRAS/CRAF. This also brings forward the idea of
developing a specific RICTOR inhibitor.
Additionally, in comparing the various targeted drugs and their effects on cell
viability, apoptosis was measured via the detection of cleaved PARP levels (Cl-PARP)
across the panel of drug treatments. In concordance with our proposed hypothesis
that a dual pathway inhibition strategy targeting both, the mTOR and MAPK
pathways, is an effective solution in RICTOR/KRAS-altered molecular settings, our
results here show that the greatest apoptotic induction is seen when using AZD2014
in combination with AZD6244 (Figure 21A). When RICTOR alone is knocked down,
we do not see significant upregulation of cleaved PARP even though p-AKT levels
decrease, suggesting that the compensatory activation of the MAPK pathway, through
upregulated p-MEK1/2, is allowing the cells to sustain viability by promoting alternate
survival mechanisms, as evidenced in section 5.3 below.
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Figure 21. Compensatory MEK1/2 activation following RICTOR knockdown
may be mediated through de-repression of inhibitory CRAF phosphorylation.
(A) H23 cells were treated with the indicated siRNAs for a total of 72 hours and
compounds were administered for 24 hours (all at 1µM, except AZD6244 at 5µM)
before cells were harvested. Western blot analyses was performed and
densitometric quantification done using Image Studio Lite 5.0 software and bands
were normalized to the respective β-Actin control bands. (B) Percent inhibition of pCRAF S259 plotted per sample relative to the average of Parental and NTC
samples. (C) Model illustrating the proposed mechanism of p-MEK1/2 activation
following RICTOR knockdown in KRAS mutant cells.
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5.3 Human p-MAPK array reveals RICTOR knockdown affects the activity of
several mediators of cellular stress and survival pathways.
We next subjected our RICTOR amplified, KRAS mutant cell line, H23, to a
human p-MAPK array which allows us to monitor the phosphorylation levels of 26
kinases. We treated H23 cells with NTC or siRICTOR for 72 hours, and following
whole-cell lysis, incubated the lysates with the phosphorylation specific array. Figure
22A shows differences of band intensities (in duplicates) for 26 different kinases
involved in the major MAPK pathways. Western blotting was performed separately on
the NTC and siRICTOR lysates to confirm effective RICTOR knockdown (Figure 22B).
Only kinases that were differentially activated (phosphorylated) were marked with
corresponding numbers and ultimately quantified to evaluate difference in activity
(Figure 22C). Densitometric quantification found several MAPK-related kinases that
were downregulated following RICTOR knockdown. Notably, we found decrease in
phosphorylation levels of CREB (S133), HSP27 (S78/82), and p38a (T180/Y182).
Interestingly, these MAPK pathway effectors are found to play broad roles as key
mediators of cellular stress response, survival, and proliferation (47, 134-136). These
results open several possible mechanisms by which RICTOR, either through an
mTORC2-dependent or independent process, is able to contribute to the oncogenic
properties of NSCLC revealed by our work, by mediating the MAPK pathway(s).
Future experiments are still needed to fully decipher these potential mechanisms.
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Figure 22. Human p-MAPK array reveals RICTOR is linked to several
mediators of cellular stress and survival. (A) Whole-cell extracts from H23 cells,
treated with a NTC or siRICTOR for 72 hours, were incubated with the Human pMAPK array, and phosphorylation status of 26 kinases was captured from a 5
minute exposure to X-ray film. (B) Western blotting analysis of lysates used for
array shows knockdown efficiency of siRICTOR. (C) Densitometric quantification of
selected phospho-kinases (in duplicates) marked by corresponding numbers.
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Chapter 6
Results
6.1 RICTOR knockdown enhances the pharmacologic efficacy of MAPK pathway
inhibition in RICTOR/KRAS-altered NSCLC cell lines
To exploit the compensatory MAPK pathway activation seen following RICTOR
signaling inhibition, we evaluated the effect of blocking the MEK-ERK signaling
pathway via pharmacologic agents alone or in combination with genetic RICTOR
blockade, in specific KRAS co-mutational settings in vitro. We tested two currently
available allosteric MEK1/2 inhibitors, selumetinib (AZD6244) and trametinib
(GSK1120212), either alone or in combination with shRICTOR treatment in three
RICTOR amplified, KRAS mutant shRICTOR inducible cell lines via MTT assay
(Figure 23A). Pharmacologic disruption of signaling in the MEK-ERK pathway by
selumetinib (5 µM) or trametinib (0.05 µM) alone rendered all three cell lines resistant
(> 50% viability) at the selected doses. However, the response was more marked in
the presence of shRICTOR in combination with MEK1/2 targeted therapy, seen by a
significant reduction in cell viability compared to either inhibitor alone (P < 0.0001).
We next checked the signaling effects induced by the MEK1/2 inhibitors with or
without RICTOR knockdown by Western blotting analysis in the representative H23
cell line (Figure 23B). Single treatment with either MEK inhibitors or combined with
shRICTOR suppressed AKT and MAPK signaling pathways (seen by reduced p-AKT
and p-ERK levels, respectively) in a dose-dependent manner. In concordance with the
aforementioned cell viability results, there was a substantial increase in the cleaved
PARP (cl-PARP) levels detected in samples treated with concomitant MEK inhibitors
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and shRICTOR compared to MEK inhibition alone, signifying reduced cell viability as
a result of increased apoptosis.
A

B
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Figure 23. RICTOR knockdown enhances the pharmacologic efficacy of
MAPK pathway inhibition in RICTOR/KRAS-altered NSCLC cell lines.
(A) Inducible shRICTOR NSCLC cell lines were cultured in the presence or
absence of 2μg/mL doxycycline to induce shRICTOR knockdown, alone or in
combination with either selumetinib (AZD6244, 5μM) or trametinib (0.05μM). After
7 to 10 days of treatment, cell viability was measured by MTT assay and compared
between shRICTOR alone and in combination with MEK1/2 inhibitors. Separate
wells were stained with crystal violet on the same day to visualize and complement
cell viability data. Data are graphed as the mean percentage ± percent SD. ***, P <
0.0001.
(B) Western blot analysis of inducible H23 cell line treated with increased doses of
selumetinib (left, 1, 5, 10 μM) or trametinib (right, 5, 10, 100 nM) alone or in
combination with 2μg/mL doxycycline to induce shRICTOR knockdown for a total 6
days. Total and phospho-specific antibodies used were for levels of RICTOR, pAKT (S473), AKT, p-ERK1/2 (T202/Y204), ERK1/2, cleaved-PARP, PARP, and βActin as loading control.
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6.2 Combined mTORC1/2 and MEK inhibition is an effective therapeutic
approach in RICTOR/KRAS-altered settings and results in synergistic antitumor effects in vitro
We next wanted to investigate the efficacy of our dual pathway inhibition
approach by use of two currently available pharmacologic inhibitors either alone or in
combination across several RICTOR amplified or non-amplified NSCLC cell lines that
carry various secondary mutations in the PI3K/AKT/mTOR and/or MAPK pathways.
We performed an MTT assay after treating cells with selumetinib and/or the dual
catalytic mTORC1/2 inhibitor AZD2014 (currently in phase II clinical trials) at the
specified doses (Figure 24). In H23, H2009, and H1792 (RICTOR amplified, KRAS
mutant) cell lines, concomitant targeting of mTORC1/2 and MEK resulted in
approximately 75% reduction of cell viability in all three cell types. Of note, H23 also
harbors LKB1 and PTEN mutations, which could explain why this cell line is more
resistant to either single agent treatment when compared to H2009 or H1792. We
then tested our inhibitors in two RICTOR non-amplified cell lines, HCC44 and
HCC193, which are KRAS mutant or wild-type, respectively. In HCC44 cells,
combined selumetinib and AZD2014 treatment decreased cell viability by over 75%;
however, HCC193 cell lines were relatively resistant to either agent alone or the
combination (> 50% cell viability). To further confirm that this dual pathway inhibition
is most effective specifically in KRAS co-mutant settings, we used the isogenic human
bronchial epithelial cell lines (HBECs) previously described (137, 138), that either
have KRAS wild-type (HBEC3-KT) or KRAS G12C mutation (HBEC3-KT-G12C). Our
results indicated that in concordance with the aforementioned data in NSCLC cell
lines, HBEC3-KT cells with KRAS mutation are significantly more sensitive to the dual
76

pathway blockade of selumetinib with AZD2014 (~75% reduction in cell viability)
compared to the KRAS wild-type cells which were more resistant (~50% viability).
In addition, we assessed whether the combination therapy of both drugs
resulted in synergistic, additive, or antagonistic effects across a range of therapeutic
doses by MTS assay. H23, H2009, H1792 (RICTOR amplified, KRAS mutant) cell
lines were treated with various concentrations of AZD2014 (0.024-12.5μM) and a
fixed set of selumetinib doses (2.3, 4.6, 9.3, or 18.7μM) for 96 hours (Figure 25). We
calculated the combination index (CI) values based on the previously described ChouTalalay model (139) using ComboSyn software (ComboSyn Inc, Paramus, NJ). The
CI parameters used were: CI = 0-0.9, synergism; CI = 0.9-1.1, additive effect; CI >
1.1, antagonism. In all three representative cell lines, optimal drug dose combinations
that impose synergistic effects were found. H23 showed the highest level of
synergism in the range of AZD2014 (0.024-0.781μM) combined with selumetinib (2.3
or 4.6 μM), whereas increasing the AZD2014 and/or selumetinib combination doses
outside of these ranges resulted in a loss of synergy and caused an additive or
antagonistic effect. In H2009, we found consistent synergism across most of the
combination dose ranges used, and in H1792 the synergistic and/or additive effects
were observed in the range of AZD2014 (0.195-6.25μM) combined with selumetinib
(2.3-18.7μM). Collectively, these findings suggest that a dual pathway inhibition
approach is warranted in specific NSCLC settings where RICTOR/KRAS alterations
exist, and that careful consideration should be given when combination dosing is
performed to render most effective synergistic anti-tumor effects.
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Figure 24. Combined mTORC1/2 and MEK1/2 inhibition is an effective
therapeutic approach in RICTOR/KRAS-altered in vitro settings.
Five NSCLC cell lines (3 RICTOR amplified (red), 2 RICTOR-non-amplified
(blue)) and two immortalized human bronchial epithelial cell lines (HBECs, black)
were treated with DMSO (control), selumetinib (1 μM), AZD2014 (0.1 μM), or the
combination selumetinib (1 μM) with AZD2014 (0.1 μM). Mutation status of
KRAS, LKB1, PTEN, and EGFR are shown below each cell line. After 72 hours
of treatment, cell viability was compared to control DMSO cells and measured by
MTT assay. Data are graphed as the mean percentage ± percent SD. **, P <
0.01; ***, P < 0.0001.
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Figure 25. AZD2014 and selumetinib act synergistically to block mTOR and
MAPK pathway signaling in vitro.
Three NSCLC (RICTOR amplified, KRAS mutant) cell lines were incubated with
increasing concentrations of AZD2014 (0.024-12.5μM) and a fixed dose of
selumetinib (0, 2.3, 4.6, 9.3, 18.7 μM) for 96 hours. Controls were treated with
DMSO only. Cell viability was analyzed by MTS assay. Data are graphed as the
mean percentage ± percent SD. Combination index (CI) values were calculated
using ComboSyn software (ComboSyn Inc, Paramus, NJ). The CI parameters
used were: CI = 0-0.9, synergism; CI = 0.9-1.1, additive effect; CI > 1.1,
antagonism.
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6.3 Comparative effects of mTORC1/2 and MEK1/2 pathway inhibition in vivo
To determine whether the synergistic effects seen in vitro translated into antitumorigenic effects in vivo, we utilized our stably transduced inducible shRICTOR cell
line H1792 (RICTOR amplified, KRAS mutant) to subcutaneously establish tumor
xenografts in mice. Once tumors reached a palpable size of 150 to 200 mm3, the
animals were randomized into five treatment arms: vehicle (1% tween-80, bid),
selumetinib (25mg/kg, bid), selumetinib (25mg/kg, bid) + doxycycline feed
(600mg/kg), AZD2014 (15mg/kg, qd), and selumetinib + AZD2014 (equivalent
dosages used as per individual inhibitor treatments). Dose administration via oral
gavage was performed for a total of 22 days continuously, with tumor volumes and
mouse body weights recorded twice weekly (Figure 26 A, B).
Results show that in comparison to the vehicle (control) group, mice receiving
selumetinib with AZD2014 had the most enhanced antitumor effects compared to
single-agent treatment groups. Similarly, we saw a significant reduction of tumor
growth in the selumetinib with shRICTOR (+Doxy) treatment arm compared to control,
although the utilization of the abovementioned combination drugs still had a more
pronounced reduction in tumor volume. Interestingly, in concordance with our in vitro
H1792 cell viability MTT data (Figure 24), selumetinib treatment alone resulted in an
increased reduction of cell viability/tumor growth compared to single agent AZD2014
treatment, suggesting that this particular KRAS mutant setting (KRASG12C) is more
sensitive to MEK1/2 inhibition than mTORC1/2, despite having amplification of
RICTOR present. Furthermore, to determine whether these effects were seen without
detrimental consequences on the health and well-being of the experimented animals,
body weight of animals was measured several times a week (Figure 26B). No
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significant loss of body weight or visible signs of declined health were witnessed
during the duration of any of the treatments.
Following the last treatment dose, tumors were extracted after 3 hours
proceeding the final dose administration, and tumor lysates were prepared as
described in materials and methods section. Representative samples from each
treatment arm were subject to Western blotting analysis (Figure 26C). Results
revealed that the treatments alone and the combination inhibited their direct targets of
each inhibitor. The treatment groups incorporating selumetinib effectively blocked
downstream p-ERK1/2 signaling, AZD2014 had a marked reduction in the
downstream mTORC1/2 effectors p-AKT, p-S6RP and p-4EBP1, and shRICTOR
induction with doxycycline showed a reduction in the total RICTOR protein levels.
Collectively, these findings suggest that AZD2014 in combination with selumetinib
result in significant anti-tumor effects mediated through mTORC1/2 and MEK dual
pathway inhibition, and is an effective therapeutic strategy in RICTOR/KRAS-altered
NSCLC.
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Figure 26. Selumetinib in combination with shRICTOR or AZD2014 results
in the strongest anti-tumor activity in vivo.
(A) Athymic nude mice were inoculated subcutaneously with the inducible H1792
shRICTOR cell line. Once tumor volumes reached an average of 150 to 200
mm3, mice were randomized to each treatment group and given the respective
treatments via oral gavage daily for a total of 22 days. Tumor volumes were
measured twice weekly, and data points are presented as the mean tumor
volume ± SEM. Colored asterisks represent significant difference of that
treatment from a different treatment resembled by its respective line color. (*, P <
0.05; +, P < 0.01). (B) Average body weight of mice is displayed for each
treatment arm, and measured twice weekly. (C) Western blot analysis showing
the levels of indicated proteins in tumor lysates harvested 3 hours after last drug
treatment on day 22.
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Chapter 7
Discussion, Conclusions, and Future Directions
Lung cancer is the leading cause of cancer-related mortality worldwide, with a
dismal five year survival of less than 16% and over 1.5 million deaths annually (140).
Despite improvement in early detection strategies and standard treatment options, it
continues to have a poor prognosis. What were once considered a single disease
entity, lung tumors are now comprised of discrete genetically and clinically distinct
subtypes. NSCLC is the most prevalent type of lung cancer, and the last decade has
seen significant effort invested in the advent of rapid genomic profiling that led to
development of molecular-targeted therapy that inhibit key oncogenic drivers such as
EGFR, ALK, and RAF, resulting in dramatic responses in patients (5). However, even
though responses are seen initially, these targeting agents rarely promote complete or
durable antitumor effects especially in unselected patients, leading to acquired
resistance mechanisms and relapse. Further, effective therapeutic options still lack for
lung tumors driven by other key mutations such as in oncogenic KRAS (~30%) and
those with untargetable oncogenic drivers that are yet to be discovered (123, 141).
Moreover, it is now evident more than ever that clinical trials performed in the
absence of sufficient molecular and genetic stratification lead to poor response rates
in patients.
In this study, we aimed to identify novel actionable genetic alterations in lung
cancer by utilizing genomic profiling data from the BATTLE-2 clinical trial that targets
advanced stage chemorefractory NSCLC patients. We identified RICTOR alterations
(amplifications and/or mutations) to be present in 17.4% (16/92) of advanced stage
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NSCLC patients, including 11.9% amplifications (11/92) and 5.4% mutations (5/92).
Mutations in the RICTOR gene have not been previously characterized, and thus the
precise functional significance of these mutations is yet to be determined. To date,
only one correlative study was found from literature searches highlighting a specific
RICTOR polymorphism (rs6878291) associated to clinical benefit and that serves as
an independent risk factor for progression-free survival in a cohort of Chinese NSCLC
patients treated with platinum-based chemotherapy (142) . However, the exact
functional significance of this SNP is unknown and further validation is needed in an
independent cohort to draw any major conclusions from this study. Interestingly,
mutations in the RICTOR gene identified from the BATTLE-2 patients were all
mutually exclusive from RICTOR gene amplifications. We also surveyed early-stage
lung adenocarcinoma cases using the TCGA dataset, and identified a total 13.4%
(31/230) of RICTOR-altered cases, which included 10% amplifications (23/230) and
5.2% mutations (12/230). When we utilized the cBioPortal dataset analysis tool to
identify the frequency of RICTOR alterations across numerous different tumor types,
we found that alterations in this gene are also found in other cancers and are not
exclusive to lung tumors. However, the highest frequency of alterations was found in
NSCLC, particularly in lung adenocarcinoma. Further, in contrast to our advanced
stage BATTLE-2 cases, we identified 4 early stage cases in the TCGA dataset that
had concomitant RICTOR gene amplifications and mutations. These data might
suggest that advanced-stage tumors do not require concomitant alterations in the
RICTOR gene to drive the involved pro-tumorigenic processes, whereas some early
stage tumors require concomitant mutations. Also, it is not clear which alteration
type—RICTOR amplification or mutation—is more important in the oncogenic process
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or in terms of response to specific targeted therapies. An example of the importance
of this difference was shown in a report analyzing mutations versus amplifications of
the gene, KIT, in melanomas, and found that patients with KIT mutations had
responses to the tyrosine kinase inhibitor, imatinib, whereas those with amplifications
had no response (143). As noted above, a closer examination of the functional
significance of these mutations is required to fully decipher their implications in
NSCLC tumorigenesis. Experimental approaches such as site-directed mutagenesis
or targeted CRISPR-Cas9 approaches in vitro can be utilized to aid in such studies.
Gene amplifications refer to the increase in copy number levels of a gene
within the genomic DNA of a cell. Amplification of a gene typically involves the
overexpression of the gene product, consequently leading to selective advantages for
tumor cell growth. We were interested to evaluate the correlation between RICTOR
amplification and RICTOR gene expression in our two datasets. Our findings show
that there was a significant direct correlation between RICTOR gene amplification and
RICTOR mRNA expression in the early stage TCGA dataset, and a trend seen in the
advanced stage BATTLE-2 lung adenocarcinoma cases. It is important to note that
when we performed this analysis including all NSCLC subtypes from the BATTLE-2
cases (total of 159 cases that were subjected to DNA NGS profiling), there was
statistical significance of direct correlation between RICTOR gene amplification and
RICTOR mRNA expression (data not shown). These differences in significance could
be due to either the smaller sample size of RICTOR amplified lung adenocarcinoma
cases being a limitation factor, or that in other NSCLC subtypes (e.g. small-cell lung
carcinomas), increased RICTOR copy number levels definitively drive the mRNA
expression of RICTOR in those tumor histotypes. Another possibility could be
88

differences in epigenetic and micro-RNA (miRNA) regulatory mechanisms in these
tumors. One such example is a study that found that DNA hypermethylation silences
miR-218 in oral squamous cell carcinoma, which directly targets RICTOR and
suppresses its expression and activity (112). Another study showed that the
downregulation of miR-153 resulted in increased RICTOR mRNA and protein
expression and tumorigenic activity, explaining the upregulation of RICTOR seen in
human glioma tissues and cell lines (144).
We next wanted to determine the association of RICTOR alterations to
prognosis using our clinical datasets. Since we have mutation data from our BATTLE2 and TCGA datasets, we checked whether there is association between
dichotomizing RICTOR amplified, mutated, or altered (combining amplified/mutated)
cases versus non-altered cases, and correlated these parameters to overall survival
and progression-free survival (data not shown). Results yielded a lack of statistical
significance between all these analyses, most likely due to inadequate statistical
power as a result from the limited number of mutant cases. Since we found an overall
direct correlation between RICTOR amplification and mRNA expression, we next
analyzed whether levels of RICTOR mRNA expression associated to outcome in our
datasets. For this analysis, in addition to our BATTLE-2 (advanced stage) and TCGA
(early stage) cases, we utilized the PROSPECT cases, a dataset our laboratory
possesses, which is comprised of early stage surgically resected lung
adenocarcinoma tumors, in which we have mRNA expression and clinical outcome
data. We performed a univariate overall survival analysis of RICTOR mRNA
expression using the Cox proportional hazards model. We found a significantly worse
overall survival in patients with advanced stage lung adenocarcinoma in the BATTLE89

2 cases. We also noted poor prognosis in our early stage surgically resected lung
adenocarcinoma cases from the PROSPECT dataset; however, no significance was
seen in patients from the TCGA dataset. One possible explanation could be that in
heavily pre-treated advanced stage cases (BATTLE-2), RICTOR serves a more
dominant role in driving malignant phenotypes of tumors and has an important
interplay with co-oncogenes such as KRAS, ultimately leading to a worse survival of
patients due to the severity of mutational burden. Similarly, although the PROSPECT
cases are still considered early stage cases relative to the BATTLE-2 cohort, these
tumors are more advanced compared to the TCGA lung adenocarcinomas. On the
contrary, in the TCGA cases, the mutational load is lower due to the early stage and
less treatment exposure, and therefore RICTOR serves more as a secondary driver
and requires, in some cases, to harbor concomitant mutations and amplifications in
RICTOR to perhaps drive cancer progression. Although the true prognostic
implications of RICTOR remain unclear in the context of NSCLC, a more expanded
analysis of larger study cohorts may provide more conclusive information on
RICTOR’s predictive and prognostic role. To date, RICTOR’s association with
prognosis has been proposed in some tumor types with differing conclusions. For
instance, RICTOR mRNA and protein expression was determined to be an
independent prognostic factor for endometrial carcinoma (145). Also, RICTOR mRNA
expression was identified as an independent prognostic indicator for disease-free
survival in patients with hepatocellular carcinoma (146). Conversely, elevated
RICTOR mRNA expression was found in normal breast tissues, lower tumor grade,
and correlated with a significantly better disease-free and overall survival (147).
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A recent study by Cheng et al. highlighted RICTOR amplification as a distinct
subset of lung cancer patients, and reported RICTOR amplifications in 8.4% of lung
adenocarcinomas from an independent cohort (Foundation Medicine, Inc.) (117). Of
these, 11% of the cases harbored RICTOR amplification as the sole potentially
actionable target out of a targeted gene panel. In concordance with our data, the
study highlighted the oncogenic role of RICTOR by showing that RICTOR inhibition
resulted in reduced cancer cell growth and cell survival in NSCLC cells amplified for
RICTOR. Moreover, their data indicated that dual mTORC1/2 inhibition was effective
against RICTOR amplified lung cancer cells. They further reported one patient
(harboring RICTOR amplification as the single actionable genomic alteration found)
that underwent treatment with dual mTORC1/2 therapy, and had over 18 months of
tumor stabilization. Although the strategy of dual mTORC1/2 therapy for RICTOR
amplified cases seems reasonable in settings where the only major oncogenic
actionable driver is RICTOR, our data presented here suggest that this treatment
strategy may not be as effective in lung tumors where other genomic aberrations are
present.
To gain insight into the co-mutational landscape that exists in RICTOR-altered
cases, we utilized the cBioPortal platform to survey the TCGA dataset for enrichment
of specific pathway alterations that are known to be deregulated in lung cancers. We
examined the frequency of alterations (mutations and/or copy number changes) in
genes known to mediate key pathways, including tyrosine kinase (RTK) signaling,
mTOR signaling, MAPK signaling, and oxidative stress response. Of great interest,
we found co-mutational enrichment of alterations in genes involved in the oncogenic
MAPK pathway, including KRAS, NF1, BRAF, and CRAF. The elevated frequency of
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these co-mutations suggested that RICTOR could potentially serve as an important
co-oncogenic driver in lung cancer progression in specific molecular settings. KRAS
has been an orphan target, and numerous attempts in its direct and even indirect
targeting have failed (88). Therefore, a great shift in focus over the years has
occurred to study and potentially inhibit downstream or parallel effector pathways and
molecules. Additionally, characterizing the genomic landscape of KRAS mutant lung
tumors is critical to better determine co-driver alterations that when identified and
appropriately targeted, can re-sensitive RAS-driven tumors to the given therapeutic
modalities. These results tailored our experimental efforts and focus on characterizing
the significance of RICTOR in the context of NSCLC, specifically in a KRAS comutational setting
Our in vitro cell line models were carefully selected to reflect the heterogeneity
of NSCLC and specific mutations in the MAPK pathway. Cell lines selected were
either RICTOR amplified or non-amplified, and included various co-mutations in
KRAS, PTEN, PIK3CA, STK11, and/or EGFR. Similar to our clinical findings that
RICTOR amplified cases directly correlated with RICTOR mRNA expression, we
found that our RICTOR amplified cell lines had a significantly higher RICTOR protein
expression compared to non-amplified cell lines. This is supportive of the idea that
amplification of this gene drives the overexpression of the protein product, perhaps
leading to increased malignant effects.
Since RICTOR’s roles in tumorigenesis are actively emerging, both dependent
and independent of the mTORC2 complex, we sought to characterize the phenotypic
consequences of modulating the levels of RICTOR in our in vitro cell line panel to
better understand RICTOR in the context of NSCLC. We found that RICTOR
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knockdown significantly reduces the clonogenic and anchorage-independent growth
of RICTOR amplified cells. In assessing its role on the tumorigenic potential in a more
physiologically relevant in vivo settings, we found that knocking down RICTOR in
H1792 and H23 (RICTOR amplified, KRAS mutant) xenografts significantly abrogated
the tumorigenicity of these cells in nude mice. These results are in concordance with
other studies showing that in various tumor types, including gliomas, bladder, ovarian,
and prostate cancers, RICTOR contributes oncogenic properties (103, 117, 148, 149).
Moreover, when we performed migration and invasion assays, we found that
RICTOR knockdown in RICTOR amplified cell lines significantly abrogated the
migrative and invasive capacity of these cells. RICTOR’s role in migration and/or
invasion has been previously reported. For example, several reports have shown that
in glioma and bladder cancer cell lines, the genetic silencing of RICTOR significantly
reduced cell growth, migration and invasion (103, 148). In addition, Lamouille et al.
have shown that the mTORC2 complex is an essential downstream mediator of TGFβ signaling, affecting cellular migration (through regulation of focal adhesions in
response to paxillin expression), invasion (through induction of MMP9 expression),
and cancer cell dissemination (through EMT-associated cytoskeletal and gene
expression changes) (150). Moreover, the RICTOR/mTOR complex has been
reported to modulate the activity of PKCα in regulating the actin cytoskeleton to impair
cell motility (41); however, this mechanism could be cell type specific, as another
study was unable to determine similar findings upon treatment with classic PKC
inhibitors to reverse this phenotype (151). Instead, their findings suggested that
RICTOR interacts and specifically regulates PKCζ activation to induce cancer cell
metastasis in an mTORC2-independent manner (151). On the contrary, Das et al.
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reported that suppression of RICTOR actually resulted in an increased invasive
capacity of glioma cells by enhancing the expression of MMP9 through a RAF1-MEKERK mediated pathway (152). Perhaps one of the more convincing pieces of
evidence shedding light on RICTOR’s independent role on regulating cell migration
was elucidated in a study showing that loss of RICTOR leads to the induction of
RhoGDI2, which disrupts cell migration via the inhibition of RAC1 and CDC42
GTPase activity (106). Both of these GTPases have been shown to regulate cell
motility and the actin cytoskeleton (153). Interestingly, in our studies, the trend of
downregulation of cell migration and invasion following RICTOR abrogation was
observed specifically in RICTOR amplified cell lines that also carried concomitant
KRAS mutations (H23, H2009, and H1792). We did not observe this trend in RICTOR
amplified but KRAS wildtype cell lines (H2172, H2126). KRAS has been previously
linked to regulating migration and invasion in various cancer types. Specifically,
mutant KRAS has been shown to promote invasion and metastasis in pancreatic
cancer through regulation of GTPase pathways involving RhoGAP5, RalA, and CAV-1
(154). Additionally, Sunaga et al. showed that oncogenic KRAS in NSCLC induces
interleukin-8 overexpression to promote cell migration (155). Although the mechanism
underlying the role of RICTOR, specifically in the context of mutant KRAS, in
regulating migration and invasion was outside of the scope of this project, it would be
interesting to show which, if any, of these previously reported mechanisms occur in
our cell types, and whether mutant KRAS has a direct involvement in mediating these
phenotypes in our cell types.
Furthermore, to better understand the phenotypic consequences described
thus far, we wanted to evaluate if RICTOR affects cell proliferation. From our
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experimental results, we found that silencing RICTOR in our amplified cell lines
resulted in a significant reduction in cell number over time. Also, we found that there
was a slight increase in G0/G1 cell cycle arrest as seen in our FACS cell cycle
experiments. Western blotting analysis further confirmed that there was a decrease of
cyclin D1 levels following RICTOR knockdown in the H23 cell line tested. Other
studies have linked the regulatory effects of RICTOR/mTORC2 to cell cycle
progression. For instance, depletion of RICTOR resulted in increased G1 phase arrest
caused by downregulation of cyclin D1, resulting in reduced proliferation and
anchorage-independent growth in pancreatic and breast cancer cell lines (115). In
agreement, a similar link was described in melanoma cells overexpressed with
RICTOR which led to increased proliferation, colony formation, and cyclin D1
expression (127). Similarly, in hepatocellular carcinoma cells, targeted inhibition of
RICTOR, but not RAPTOR, promoted G0/G1 cell cycle arrest and was explained by
the reduced phosphorylation of p-AKT S473 levels, suggesting that hydrophobic motif
phosphorylation of AKT may be required for the maintenance of cyclin D1 expression
(129). There could be various mechanisms by which RICTOR’s effects on cell cycle
progression are mediated. One mechanistic basis of the reduction of cyclin D1 was
shown in a study that pinpointed to the inhibition of mTORC2 triggering a proteasomemediated cyclin D1 degradation via a GSK3-dependent manner, and suggested that
specifically RICTOR, as part of mTORC2, is responsible for increasing the stability of
cyclin D1 (128). This study further highlighted that although AKT is known to positively
regulate cyclin D1 stability through the negative phosphorylation and inactivation of
GSK3 (156), the reduced levels of cyclin D1 are independent of AKT. Other studies
have reported that mTORC2 targeting suppresses cyclin D1 translation by inhibiting
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the recruitment of cyclin D1 mRNA to polysomes in certain leukemia cells (157, 158),
since the downstream AKT/mTORC1 translational repressor, 4E-BP1, is known to be
involved in the regulation of cap-dependent mRNA translation and can also be
deactivated upon mTORC2 inhibition (29, 159). However, further investigation is
needed to precisely decipher the relationship between RICTOR/mTORC2, AKT, and
4E-BP1 in cell cycle progression.
The consequences of RICTOR inhibition from our studies clearly highlighted
the significance of this oncogene in the context of NSCLC. We next wanted to
characterize the cell signaling patterns associated with RICTOR in our cell line panel.
Our findings demonstrated that exclusively in KRAS co-mutational backgrounds,
knockdown of RICTOR resulted in a compensatory increased activation of
phosphorylated MEK1/2 levels compared to controls. We further discovered that this
compensation occurs in both RICTOR amplified and non-amplified settings,
suggesting that regardless of the increased expression of RICTOR in amplified cells,
there is an important interplay between RICTOR and mutant KRAS in mediating
crosstalk mechanisms between the mTOR/AKT and RAS/MEK pathways. Our in vitro
work further uncovered that when we perform concomitant knockdown of RICTOR
and KRAS, there is no increase in p-MEK levels, suggesting that mutant KRAS is
required for this compensatory mechanism to occur.
To further define a potential mechanism mediating this crosstalk between these
two parallel oncogenic pathways, we tested the hypothesis that the compensatory
activation of p-MEK1/2 following RICTOR blockade is mediated through the derepression of the inhibitory CRAF S259 phosphorylation as a result of decreased
activation of AKT, leading to a more active CRAF involved in transduction of mutant
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KRAS signaling. Previous reports have identified this negative crosstalk mechanism
between AKT and CRAF in certain cellular contexts (49, 54, 55). In our tested H23
cell line, we found that genetic inhibition of RICTOR decreased p-AKT levels and as a
result, reduced the phosphorylation of CRAF S259, suggestive of increased CRAF
activity. When we tested the mTORC1 inhibitor everolimus, we did not find a
significant reduction in the phosphorylation levels of CRAF, in line with the displayed
elevated p-AKT levels, and in agreement with previously described AKT feedback
loops following mTORC1 inhibition (130, 131). When we combined siRICTOR in
combination with everolimus, there was a similar reduction of p-CRAF S259 levels as
siRICTOR alone, displaying the lack of mTORC1 contribution to this crosstalk
mechanism. Interestingly, treatment with our dual mTORC1/2 inhibitor, AZD2014, had
only a slight effect on decreasing the inhibitory p-CRAF levels, despite having a
pronounced reduction in p-AKT levels. These data suggest that RICTOR may have a
unique interplay with AKT in mediating the CRAF cross-talk activity, independent of
mTORC1 and mTORC2. Similar to our finding, a study by Das et al. showed that
RICTOR ablation enhanced the phosphorylation of MEK, ERK, and also increased the
CRAF kinase activity in glioma cells (152). In further support of the preliminary
evidence shown here, there have been several reports signifying the importance of
CRAF in the context of mutant KRAS. For example, in KRAS-driven NSCLC, CRAF,
rather than BRAF, was determined to be the critical effector in mediating KRAS
signaling (160). Similarly, Karreth et al. has shown that KRASG12D mutations elicit their
oncogenic effects primarily through CRAF in a lung cancer mouse model, whereas
BRAF is dispensable (161). Voice et al. has shown that of all the human RAS
homologs tested, KRAS was revealed to be the most significant activator of CRAF in
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vivo (162). In line with this, Lito et al. showed convincing evidence that in KRAS
mutant tumors, effective MEK inhibition (and essentially MAPK pathway
downregulation) requires the disruption of CRAF mediated MEK activation (163).
Taken together, although our preliminary mechanistic findings here suggest a
possible link between RICTOR/AKT-mediated regulations of CRAF activity in a KRAS
mutant setting, further investigation is warranted. For example, it would be interesting
to study the effects of genetic or targeted inhibition of AKT in this setting to
conclusively confirm this negative crosstalk. Furthermore, it would be important to
perform immunoprecipitation experiments to see if RICTOR, AKT, and/or CRAF
directly bind in this particular cell line, and whether other mTORC2 components are
involved. This will elucidate whether RICTOR is acting upon AKT independently of
mTORC2 in this cell type, as prior studies have shown this to be a possibility (108,
109). Lastly, since this experiment was performed in one cell line (H23, RICTOR
amplified, KRAS/STK11/PTEN mutant), it would be imperative to expand this study in
other cell lines, particularly those that do not possess RICTOR amplification and/or
the other listed co-mutations. This would shed light as to which specific genomic
landscape the crosstalk occurs in, as it is well established that the complex
heterogeneity of even cell lines results in differential signaling mechanisms.
As we continued to explore the cell signaling effects mediated by RICTOR in
our RICTOR amplified cell lines, we performed a phospho-MAPK proteomic array on
our H23 cell line to compare siRICTOR versus control cells. We found that RICTOR
inhibition decreased the phosphorylation and activation levels of p38α, CREB, and
HSP27. Interestingly, these kinases have broad roles in mediating cellular stress
response, survival, and/or proliferation, in which some of the signaling pathways and
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functionalities overlap, especially since these kinases can, in fact, regulate one
another (47, 134). Notably, the most significant difference in phosphorylation was
seen in p38α, which has been reported to have both tumor suppressive and
oncogenic roles, depending on the cellular context. Although some reports have
shown prosurvival functionalities, many others have associated this kinase with the
induction of apoptosis during cellular stress (47). Another report confirmed similar
results as ours, showing that in mice in which RICTOR is conditionally knocked out in
the liver, phospho-proteomic profiling identified a significant reduction in the p38
MAPK levels in vivo (164). In connection to our abovementioned cyclin D1
downregulation and slight increase in cell cycle arrest after RICTOR inhibition, p38
has been shown to negatively regulate cell cycle progression by inducing a G1/S
checkpoint in response to osmotic stress, reactive oxygen species, and cell
senescence stimuli (136). Specifically, p38 has been connected with reducing the
levels of cyclin D1 either through an indirect transcriptional repression mechanism
(165, 166), or through direct phosphorylation of cyclin D1, resulting in ubiquitination
and proteosomal degradation (135). These data suggest that there could be a link
between RICTOR and p38α in modulating the cell cycle progression and cellular
stress response in the NSCLC cell lines tested. Accordingly, accumulating evidence
has shown that RICTOR/mTORC2 is linked to the regulation of metabolic stress,
inflammatory response, and energy balance in various contexts (167-170).
Furthermore, it is interesting to note that since we determined a compensatory
activation of p-MEK following RICTOR inhibition, it is plausible that this activated MEK
could bypass ERK and interact with p38α to mediate alternate survival pathways such
as autophagy. A study by Wang et al. demonstrated that MEK may play a more
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important role by bypassing ERK and regulating BECLIN-1 expression to induce
autophagy, emphasizing a non-canonical MEK-ERK signaling pathway (171). In line
with this assumption, genetic ablation or targeted inhibition of p38α was shown to
cause cell cycle arrest and autophagic cell death in colorectal cancer cells (172). A
more detailed mechanistic study assessing various markers of autophagy,
senescence, proliferation, and/or apoptosis is needed to fully ascertain the
mechanism by which we see a reduction in colony formation, cell counts, and
tumorigenicity following RICTOR inhibition in our pre-clinical NSCLC models.
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signaling pathways are critical
integrators of mechanisms mediating cell survival, proliferation, differentiation,
metabolism, and invasion/migration in response to extracellular stimuli. Various
targeted therapies have been developed directed at each of these major oncogenic
pathways (173, 174). However, it is now clear that monotherapeutic targeting of
effectors of these pathways result in resistance mechanisms such as re-activation of
feedback loops and cross-talk mechanisms. Thus, these acquired bypass
mechanisms are to blame for the lack of therapeutic efficacy and relapse often seen
in patients, and therefore prompt the use of combinatorial therapeutic strategies. Our
in vitro and in vivo data suggest that RICTOR blockade results in a compensatory
activation of the MAPK pathway, specifically in KRAS co-mutational settings. We
show that in both RICTOR amplified and non-amplified NSCLC cell lines, RICTOR
knockdown increases p-MEK levels only when the cells harbor KRAS mutations. This
is important as mutations in KRAS have been identified in 20-30% of lung cancers
and are known to serve as crucial drivers of this malignancy, leading to poorer
prognosis and resistance to chemo- and targeted therapies, yet KRAS still remains an
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orphan target in NSCLC and other tumors (3, 175). To date, direct targeting of
aberrant KRAS activation has been unsuccessful despite significant research efforts
(176). We exploited this resistance mechanism as a therapeutic vulnerability and
therefore tested a dual pathway inhibition approach by use of a catalytic mTORC1/2
inhibitor (AZD2014) and allosteric MEK1/2 inhibitor (selumetinib). Our results suggest
this combination renders a highly synergistic anti-tumor effect in our RICTOR/KRASaltered NSCLC cell lines both in vitro and in vivo.
Combination strategies with other inhibitors targeting both pathways have been
proposed and reported, but with varying efficacy and in differing genomic subsets. A
study by Meng et al. found that combining selumetinib with an AKT inhibitor (MK2206)
had a significant synergistic effect on tumor growth in vitro and in vivo in NSCLC
(177). However, they found no correlation between mutational status of KRAS, EGFR,
BRAF, or PI3K to sensitivity to either drug. Moreover, a study reported that activation
of the PI3K pathway strongly influences sensitivity to MEK inhibition in RAS mutant
cells, and thus suggest a combination therapy of PI3K and MEK inhibitors for tumors
with concomitant mutations of KRAS and PIK3CA (178). However, the role of
RICTOR in PI3K co-mutational settings is yet to be determined.
Similar to our proposed strategy, a recent in vitro study signified the rationale of
combined inhibition of MEK and mTOR signaling in KRAS mutant NSCLC (179). They
assessed a panel of EGFR/ALK wildtype NSCLC cell lines that are either KRAS
mutant or wildtype, and have shown that inhibition of mTOR is dominantly responsible
for the majority of growth inhibition in the combination therapy of mTORC1/2 inhibitor
(AZD2014) with MEK1/2 inhibitor (trametinib), and the combination is more effective in
KRAS mutant lines. Interestingly, our in vitro data testing selumetinib and AZD2014 in
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KRAS mutant cells did not define a clear dominant trend between which drug has the
more potent effect on cell viability, perhaps due to the diverse co-mutational nature of
the RICTOR cell line panel. This could also be due to the differences in the MEK
inhibitor used (selumetinib vs. trametinib), which are known to have differing
mechanisms of action. Additionally, our in vivo data using the H1792 xenograft model
actually showed that selumetinib had a more enhanced anti-tumor effect as a single
agent compared to the mTORC1/2 inhibitor AZD2014, suggesting that this particular
KRAS mutant cell line (KRASG12C) is more sensitive to MEK1/2 inhibition than
mTORC1/2, despite having amplification of RICTOR present.
Nevertheless, these reports and others underscore the combinatorial rational of
dual pathway inhibition presented here. It would be of interest to elucidate, however,
whether the development of specific pharmacologic targeting of RICTOR would prove
beneficial in defined patient populations, namely in RICTOR amplified cases,
exclusive of other major driver mutations. This would prove beneficial considering that
RICTOR is known to function independently of the mTORC2 complex, regulating
other effectors involved in tumor progression. However, in the patient cohort that we
are targeting here, we believe that dual mTORC1/2 inhibitors, such as AZD2014, are
still warranted further clinical testing in combination with MEK inhibitors, such as
selumetinib, as this approach prevents the compensatory feedback we described in
our study, and other mechanisms often seen by single mTORC1 inhibitors known to
induce hyperactivation of PI3K-AKT (180). Moreover, although previous reports
suggest limited clinical benefits from mTORC1/2 inhibitors, proper patient selection in
lung cancer patients is needed to fully exploit this therapeutic option (181). Lastly,
although combination therapy might be highly effective in cancer patients, there are
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great limitations in regards to toxicity. In our proposed strategy specifically, the mTOR
and MAPK signaling pathways regulate important physiological functions in nonmalignant cells, and thus, an extended treatment setting targeting both pathways
might not be feasible. It is therefore important to assess various dosing strategies
(e.g. intermittent versus continuous treatment) to fully define the maximal tolerated
frequency/doses with the lowest toxicity profile.
In conclusion, our study uncovers defined molecular settings by which we
believe can impose clinical benefit to KRAS mutant NSCLC by screening for
concomitant RICTOR alterations that will determine potential benefit from dual
mTOR/MAPK pathway inhibition. Excitingly, an ongoing clinical trial termed
“TORCMEK” (NCT02583542) is recruiting patients with advanced cancers, including
triple-negative breast cancer and NSCLC (KRAS mutant vs. wild-type tumors), to
assess feasible dose levels and clinical activity of combining AZD2014 in combination
with selumetinib. Despite that these targeting agents have been utilized in other
clinical trials as single agents or in combination with alternative drugs, this specific
combination has not been tested in the clinical setting. On the basis of our studies, it
would be of interest to identify if any potential responders to this combination
harbored RICTOR and/or KRAS alterations.

103

Chapter 8
Appendix
The manuscript described below has been submitted for publication and includes the
data presented in the results section of this dissertation.
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